# Prognostic and predictive microRNA panels for heart failure patients with reduced or preserved ejection fraction: a meta-analysis of Kaplan-Meier-based individual patient data.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12235814</article-id><article-id pub-id-type="pmid">40624658</article-id>
<article-id pub-id-type="publisher-id">4238</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04238-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Prognostic and predictive microRNA panels for heart failure patients with reduced or preserved ejection fraction: a meta-analysis of Kaplan&#x02013;Meier-based individual patient data</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Parvan</surname><given-names>Reza</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Becker</surname><given-names>Victoria</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hosseinpour</surname><given-names>Milad</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Moradi</surname><given-names>Yousef</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Louch</surname><given-names>William E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cataliotti</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Devaux</surname><given-names>Yvan</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Frisk</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Silva</surname><given-names>Gustavo Jose Justo</given-names></name><address><email>g.j.j.d.silva@medisin.uio.no</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" id="IA1"><collab>AtheroNET COST Action CA21153</collab></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00j9c2840</institution-id><institution-id institution-id-type="GRID">grid.55325.34</institution-id><institution-id institution-id-type="ISNI">0000 0004 0389 8485</institution-id><institution>Institute for Experimental Medical Research, </institution><institution>Oslo University Hospital and University of Oslo, </institution></institution-wrap>Oslo, Norway </aff><aff id="Aff2"><label>2</label>KG Jebsen Center for Cardiac Research, Oslo, Norway </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03w04rv71</institution-id><institution-id institution-id-type="GRID">grid.411746.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 4911 7066</institution-id><institution>Department of Medical Genetics, School of Medicine, </institution><institution>Iran University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01ntx4j68</institution-id><institution-id institution-id-type="GRID">grid.484406.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0417 6812</institution-id><institution>Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, </institution></institution-wrap>Sanandaj, Iran </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/012m8gv78</institution-id><institution-id institution-id-type="GRID">grid.451012.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0621 531X</institution-id><institution>Cardiovascular Research Unit, Department of Precision Health, </institution><institution>Luxembourg Institute of Health, </institution></institution-wrap>Strassen, Luxembourg </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01xtthb56</institution-id><institution-id institution-id-type="GRID">grid.5510.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8921</institution-id><institution>Department of Molecular Medicine, Institute of Basic Medical Sciences, </institution><institution>University of Oslo, </institution></institution-wrap>Oslo, Norway </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>409</elocation-id><history><date date-type="received"><day>25</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>6</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par9">Cardiac troponins and natriuretic peptides are benchmark biomarkers for heart failure (HF) with reduced ejection fraction (HFrEF) but have limited prognostic performance for HF patients with preserved ejection fraction (HFpEF). Non-coding RNA-based biomarkers represent an innovative approach to risk-stratify patients and might address the unmet need for minimally invasive prognostic and predictive tools for HF development and HF-related outcomes. Our aim is to investigate the prognostic performance and risk stratification potential of circulating panels of microRNAs (miRNAs) in HFrEF and HFpEF.</p></sec><sec><title>Methods</title><p id="Par10">A systematic search on PubMed, Web of Science, and Scopus databases was performed for studies reporting miRNAs as prognostic biomarkers in HF patients. A total of 22 studies pooling 5736 participants were included for quantitative analysis. KM-based individual patient data (IPD) analysis was performed in 12 studies (5064 participants).</p></sec><sec><title>Results</title><p id="Par11">KM-based IPD analysis in HFrEF allowed the identification of a panel of four miRNAs (miR-27a-3p, miR-129-5p, miR-145-5p, and miR-590-3p) predicting the risk of all-cause death with hazard ratio (HR) 4.26 [2.68&#x02013;6.76]. MiR-122-5p and miR-423-5p predicted cardiovascular death of HFrEF patients (HR 3.61 [2.67&#x02013;4.87]). In HFpEF, miR-19a-3p predicted all-cause death of HFpEF patients with HR 2.23 [1.16&#x02013;4.27]. Moreover, a panel of eight miRNAs (miR-17-5p, miR-20a-5p, miR-21, miR-23, miR-27, miR-106b-5p, miR-210, and miR-221) showed significant association with HF incidence (HR 2.14 [1.81&#x02013;2.53]).</p></sec><sec><title>Conclusions</title><p id="Par12">A comprehensive meta-analysis of KM-based IPD enabled the identification of unique miRNA panels predicting the incidence and severity of HFrEF and HFpEF, supporting the clinical usefulness of miRNA profiling for tailored healthcare and risk stratification in HF patients. Nonetheless, more rigorously designed longitudinal studies are needed to validate the clinical application of miRNAs as prognostic and predictive biomarkers.</p></sec><sec><title>Graphical Abstract</title><p id="Par13">
<graphic position="anchor" xlink:href="12916_2025_4238_Figa_HTML" id="MO1"/>
</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04238-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Heart failure</kwd><kwd>HFrEF</kwd><kwd>HFpEF</kwd><kwd>MicroRNA</kwd><kwd>Biomarker</kwd><kwd>Risk stratification</kwd></kwd-group><funding-group><award-group><funding-source><institution>COST Association</institution></funding-source><award-id>CA17129</award-id><award-id>CA17129</award-id><award-id>CA17129</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>EU Horizon 2020 project COVIRNA</institution></funding-source><award-id>101016072</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>National Research Fund</institution></funding-source><award-id>C17/BM/11613033</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Ministry of Higher Education and Research</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Heart Foundation-Daniel Wagner of Luxembourg</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Norwegian Association for Public Health</institution></funding-source><award-id>16040</award-id><award-id>19560</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Research Council of Norway</institution></funding-source><award-id>303150</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>University of Oslo (incl Oslo University Hospital)</institution></funding-source></award-group><open-access><p>Open access funding provided by University of Oslo (incl Oslo University Hospital)</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec2"><title>Background</title><p id="Par35">Heart failure (HF) has been studied extensively during the last decades [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Increased clinical awareness, longer life expectancy, and global population growth all contribute to the elevated prevalence of HF worldwide [<xref ref-type="bibr" rid="CR3">3</xref>]. Presently, an estimated 64.3 million people are diagnosed with HF, making it one of the most common causes of hospitalization and death globally [<xref ref-type="bibr" rid="CR4">4</xref>]. HF is a heterogeneous syndrome that can present with various symptoms and degrees of severity [<xref ref-type="bibr" rid="CR5">5</xref>]. It can be divided into three entities based on ejection fraction (EF): HF with reduced EF (HFrEF, EF&#x02009;&#x02264;&#x02009;40%), HF with mildly reduced EF (HFmrEF, 41&#x02013;49% EF), and HF with preserved EF (HFpEF,&#x02009;&#x02265;&#x02009;50%) [<xref ref-type="bibr" rid="CR6">6</xref>]. Typically, the diagnosis is based on a combination of physical examinations, echocardiographic evaluation, and identification of circulating biomarkers. N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponins (cTns) are the most commonly used biomarkers [<xref ref-type="bibr" rid="CR7">7</xref>]. Although the combination of NT-proBNP and cTns has excellent diagnostic value in the acute setting, their prognostic applicability is limited [<xref ref-type="bibr" rid="CR7">7</xref>]. Thus, there is a need to identify relevant panels of prognostic biomarkers in combination with conventional biomarkers (NT-proBNP and cTns) for different forms of HF.
</p><p id="Par36">Circulating microRNAs (miRNAs) have emerged as potential prognostic tools to personalize healthcare of HF patients [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. MiRNAs are small non-coding RNA molecules that regulate gene expression post-transcriptionally by either inhibiting translation or promoting degradation of messenger RNA. Extracellular miRNAs are readily identifiable in blood, where their stable, non-degrading nature renders them promising biomarker targets [<xref ref-type="bibr" rid="CR10">10</xref>]. Several clinical studies have reported the use of different miRNAs as biomarkers to predict hard endpoints and capture complementary information as an additive value on traditional biomarkers [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. However, a thorough assessment of their prognostic value in HFrEF and HFpEF is lacking.</p><p id="Par37">Thus, the current study aimed to evaluate the performance of miRNAs in the prognosis of HF-related outcomes such as HF hospitalization, cardiovascular (CV) death, and all-cause death, as well as the prediction of HF incidence. Also, using the meta-analysis approach enables us to identify potential miRNA prognostic and predictive panels for HF development and risk stratification. This was executed by performing a systematic literature review resulting in aggregated meta-analysis along with reconstructed individual participant data (IPD) analysis based on published Kaplan&#x02013;Meier (KM) curves. These two approaches were combined to limit publication bias and the influence of heterogeneity of the included studies.</p></sec><sec id="Sec3"><title>Methods</title><sec id="Sec4"><title>Protocol registration and search strategy</title><p id="Par38">The current study represents a systematic review and meta-analysis encompassing six key stages: search syntax and search strategy, screening, selection, data extraction, quality assessment, and meta-analysis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to execute and report this systematic review and meta-analysis (see Additional file 2) [<xref ref-type="bibr" rid="CR14">14</xref>]. The protocol of this study has been registered in PROSPERO (CRD42021286660).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Flow diagram of study selection</p></caption><graphic xlink:href="12916_2025_4238_Fig1_HTML" id="MO2"/></fig></p></sec><sec id="Sec5"><title>Study selection and eligibility criteria</title><p id="Par39">Using a comprehensive previously reported search strategy [<xref ref-type="bibr" rid="CR15">15</xref>], we searched in PubMed (Medline), Scopus, and Web of Science databases. The search encompassed articles published up to 24 April 2024. After collecting all relevant articles, the results were imported into EndNote software version 20 for further analysis. After initial duplicate removal, two independent reviewers (R.P. and V.B.) performed title and abstract screening followed by full-text screening. Disagreements between the two reviewers were discussed to reach a consensus. Backward citation tracking was performed to avoid missing any relevant study. We included studies that assessed HF-related outcomes, including HF hospitalization, CV death, and all-cause death, as well as HF incidence if they met the following inclusion criteria: i. Patients should be diagnosed with HF based on European Society of Cardiology (ESC)/American Heart Association (AHA) guidelines and/or with an expert cardiologist; ii. At least one miRNA should be evaluated in serum or plasma; iii. At least 3 months of follow-up; iv. Retrospective and/or prospective cohort studies; v. Studies reporting acute heart failure have not been included; vi. Studies should report adjusted/non-adjusted hazard ratios and adjusted/non-adjusted odds ratios (HR/aHR and OR/aOR); vii. Reviews, systematic reviews, conference papers, and book chapters have not been included.</p></sec><sec id="Sec6"><title>Risk of bias assessment</title><p id="Par40">The risk of bias and quality of prognostic factor studies were assessed by the QUIPS (Quality In Prognosis Studies) tool [<xref ref-type="bibr" rid="CR16">16</xref>]. QUIPS consists of a tool for rating assessment of six main bias domains: study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding, statistical analysis, and reporting [<xref ref-type="bibr" rid="CR17">17</xref>]. Two independent reviewers (G.J.J.S. and M.H.) performed the questionnaire separately for each study. Disagreements between the two reviewers were resolved by Parvan and Moradi to reach consensus.</p></sec><sec id="Sec7"><title>Aggregate data meta-analysis</title><sec id="Sec8"><title>Data extraction</title><p id="Par41">Data extraction from selected studies was performed by two independent reviewers (R.P. and V.B.). The disagreement between the two was mediated by two additional reviewers, Y.M. and G.J.J.S.. Finally, the resulting database was reviewed for data authenticity by R.P. and G.J.J.S.. The extracted data has been divided into two main parts: i. General and demographic information (first author, country, study design, study population, patient recruitment period, patient age, and follow-up period) and ii. Specific information (clinical outcome, miRNA, log-rank test [<italic>p</italic> value], univariate and/or multivariate Cox proportional test [HR, 95% confidence interval (CI)], univariate and/or multivariate logistic regression test [OR, 95% CI], and adjustment factors). Data extraction was carried out initially, followed by data harmonization for all outcomes, specifically the clinical outcome of interest, through consensus reached by two independent reviewers (R.P. and G.J.J.S.).</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par42">In this study, we performed statistical analysis using Stata 17. We extracted the HRs/ORs, and the corresponding 95% CI reported for each outcome. Due to right skewed HRs/ORs, log<sub>10</sub> transformation was used to obtain a normal distribution. The random effect model (DerSimonian-Laird) was used to estimate the effect size summary, thereby considering between-study variations, particularly due to different sample sizes [<xref ref-type="bibr" rid="CR18">18</xref>]. Additionally, fixed effect model (inverse variance) was used for subgroup analysis. A <italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant. Heterogeneity analysis was performed using <italic>I</italic>-square and Cochrane&#x02019;s <italic>Q</italic> test. Based on Cochrane Library&#x02019;s criteria, 0&#x02013;25% was considered no heterogeneity, 25&#x02013;50% low heterogeneity, 50&#x02013;75% acceptable heterogeneity, and 75&#x02013;100% high and unacceptable heterogeneity [<xref ref-type="bibr" rid="CR18">18</xref>]. Subgroup studies were conducted based on HF type and outcome definition to determine the source of heterogeneity. Additionally, publication bias was assessed by performing funnel plot.</p></sec></sec><sec id="Sec10"><title>Kaplan&#x02013;Meier-based meta-analysis</title><sec id="Sec11"><title>Data extraction</title><p id="Par43">IPD was computationally reconstructed from reported KM survival curves by taking advantage of a previously established iterative approach (IPDfromKM software) developed by Liu et al. [<xref ref-type="bibr" rid="CR19">19</xref>]. Then, we checked the accuracy of reconstructed data by visual inspection of the individual KM curves derived from reconstructed data and original data, followed by the assessment of statistics of accuracy reported (root mean square error (RMSE), mean absolute error, maximum absolute error, and Kolmogorov&#x02013;Smirnov test statistics).</p></sec><sec id="Sec12"><title>Statistical analysis</title><p id="Par44">For risk stratification, all reconstructed KM curves were classified into two groups based on corresponding studies (cut-offs established for each miRNA). Then, data from all miRNAs were pooled according to their direction in their original studies. We performed survival analysis with log-rank test. A univariate Cox proportional hazard test was performed, and Harrell&#x02019;s <italic>C</italic>-statistics and Akaike information criterion (AIC) were used to identify potential panels of miRNAs with prognostic value. The criteria for selection of potential panels were based on Wald test (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) for model fit and likelihood ratio test (LRT) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), which shows the additive value of one biomarker on the existing model and area under the receiver operating characteristic curve (AUC) (&#x0003e;&#x02009;0.5) indicating the ability of a biomarker in predicting the outcome.</p></sec></sec></sec><sec id="Sec13"><title>Results</title><sec id="Sec14"><title>Study identification and quality assessment</title><p id="Par45">We identified 2778 records from three different databases: PubMed, Scopus, and Web of Science. Following duplicate removal, 2074 publications underwent title and abstract screening. Of the 524 associated studies that passed the title and abstract screening, 22 studies entered the qualitative assessment (Additional file 1: Fig. S1 and Table S2). Lastly, a total of 21 studies [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>] (comprising 5736 participants) were included in the quantitative analysis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and Additional file 1: Table S3). More than 86% of studies were found to have a low risk of bias for study participation, prognostic factor measurement, outcome measurement, and statistical analysis and reporting domains. One study [<xref ref-type="bibr" rid="CR37">37</xref>] were evaluated to have high risk of bias in study attrition (due to lack of information on dropped out participants) and four others [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] in study confounding domain (due to lack of information about confounding factors for adjustment of Cox regression analysis) (Additional file 1: Fig. S1). Two studies [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR35">35</xref>] showed moderate risk of bias in statistical analysis and reporting due to the absence of HR and KM data reporting, leading to the exclusion of one of them [<xref ref-type="bibr" rid="CR35">35</xref>] from the quantitative analysis.</p></sec><sec id="Sec15"><title>Baseline characteristics of included studies</title><p id="Par46">Table <xref rid="Tab1" ref-type="table">1</xref> shows the baseline characteristics of HF patients where relevant stratification of HFrEF and HFpEF as well as participants in the cohort studies for HF incidence. As expected, there were significant differences in BNP levels between control and HF patients. Additionally, 16 [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>] out of 22 studies reported echocardiographic measurements of EF showing a significant reduction in HF patients compared to controls. HFrEF and HFpEF patients exhibited different EF, and the proportion of females was twice as high in the HFpEF group than in the HFrEF group (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline demographics of 5789 patients from all 22 included HF-related outcomes and HF incidence</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="2"/><th align="left" colspan="7"><bold>HF-related outcome</bold></th><th align="left" colspan="2"><bold>HF incidence</bold></th></tr><tr><th align="left" rowspan="2"><bold>Num. of studies</bold></th><th align="left" colspan="2"><bold>Patients</bold></th><th align="left" rowspan="2"><italic>p</italic> value</th><th align="left" colspan="2"><bold>HF</bold></th><th align="left" rowspan="2"><italic>p</italic> value</th><th align="left" rowspan="2"><bold>Num. of studies</bold></th><th align="left" rowspan="2"><bold>Population</bold></th></tr><tr><th align="left"><bold>Control</bold></th><th align="left"><bold>HF</bold></th><th align="left"><bold>HFrEF</bold></th><th align="left"><bold>HFpEF</bold></th></tr></thead><tbody><tr><td align="left" colspan="11"><bold>Demographic</bold></td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Age, y</bold></td><td align="left">12</td><td align="left">64 [54&#x02013;67]</td><td align="left">65 [60&#x02013;67]</td><td align="left">0.9309</td><td align="left">65 [61&#x02013;67]</td><td align="left">63 [52&#x02013;75]</td><td align="left">0.9999</td><td align="left">8</td><td align="left">62 [55&#x02013;83]</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Female, %</bold></td><td align="left">13</td><td align="left">174/400 (43%)</td><td align="left">616/2183 (28%)</td><td align="left">0.0001</td><td align="left">518/1982 (26%)</td><td align="left">98/201 (54%)</td><td align="left">0.0001</td><td align="left">8</td><td align="left">2080/4062 (51%)</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>BMI, kg/m</bold><sup><bold>2</bold></sup></td><td align="left">10</td><td align="left">25.0 [24.4&#x02013;25.7]</td><td align="left">26.9 [24.9&#x02013;28.4]</td><td align="left">0.2281</td><td align="left">25.2 [24.9&#x02013;28.0]</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">6</td><td align="left">27.8 [25.1&#x02013;29.3]</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Alcohol abuse, yes (%)</bold></td><td align="left">6</td><td align="left">153/336 (45%)</td><td align="left">259/568 (46%)</td><td align="left">0.9999</td><td align="left">196/443 (44%)</td><td align="left">63/125 (50%)</td><td align="left">0.2246</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>NT-proBNP, ng/l</bold></td><td align="left">6</td><td align="left">95 [44&#x02013;146]</td><td align="left">1594 [987&#x02013;2920]</td><td align="left">*</td><td align="left">1594 [987&#x02013;2920]</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">2</td><td align="left">626 [350&#x02013;903]</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>BNP, ng/l</bold></td><td align="left">6</td><td align="left">67 [63&#x02013;104]</td><td align="left">1481 [920&#x02013;1531]</td><td align="left">0.0020</td><td align="left">1492 [1020&#x02013;1542]</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left" rowspan="5">&#x02009;&#x02009;&#x02009;&#x02009;<bold>NYHA</bold></td><td align="left"><bold>Class I,</bold>
<bold><italic>N</italic></bold>
<bold>(%)</bold></td><td align="left">3</td><td align="left">10/118 (8%)</td><td align="left">37/259 (14%)</td><td align="left">0.1315</td><td align="left">15/183 (8%)</td><td align="left">22/76 (29%)</td><td align="left">0.0001</td><td align="left">&#x02013;</td><td align="left">-</td></tr><tr><td align="left"><bold>Class II,</bold>
<bold><italic>N</italic></bold>
<bold>(%)</bold></td><td align="left">7</td><td align="left">0/346 (0%)</td><td align="left">394/753 (52%)</td><td align="left">0.0001</td><td align="left">359/677 (53%)</td><td align="left">35/76 (46%)</td><td align="left">0.2764</td><td align="left">&#x02013;</td><td align="left">-</td></tr><tr><td align="left"><bold>Class III,</bold>
<bold><italic>N</italic></bold>
<bold>(%)</bold></td><td align="left">8</td><td align="left">0/346 (0%)</td><td align="left">291/859 (34%)</td><td align="left">0.0001</td><td align="left">273/783 (35%)</td><td align="left">18/76 (24%)</td><td align="left">0.0560</td><td align="left">&#x02013;</td><td align="left">-</td></tr><tr><td align="left"><bold>Class IV,</bold>
<bold><italic>N</italic></bold>
<bold>(%)</bold></td><td align="left">6</td><td align="left">0/316 (0%)</td><td align="left">77/652 (12%)</td><td align="left">0.0001</td><td align="left">76/576 (13%)</td><td align="left">1/76 (1%)</td><td align="left">0.0010</td><td align="left">&#x02013;</td><td align="left">-</td></tr><tr><td align="left"><bold>Class III&#x02013;IV,</bold>
<bold><italic>N</italic></bold>
<bold>(%)</bold></td><td align="left">3</td><td align="left">&#x02013;</td><td align="left">297/1059 (28%)</td><td align="left">&#x02013;</td><td align="left">297/1059 (28%)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">-</td></tr><tr><td align="left" colspan="11"><bold>Blood/urine analysis</bold></td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Total cholesterol, mmol/l</bold></td><td align="left">8</td><td align="left">4.65 [4.52&#x02013;4.65]</td><td align="left">4.63 [4.47&#x02013;4.75]</td><td align="left">0.9632</td><td align="left">4.62 [4.46&#x02013;4.68]</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">7</td><td align="left">4.60 [4.00&#x02013;4.80]</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Triglyceride (mmol/l)</bold></td><td align="left">6</td><td align="left">1.37 [1.35&#x02013;1.46]</td><td align="left">1.42 [1.40&#x02013;1.44]</td><td align="left">0.9162</td><td align="left">1.42 [1.40&#x02013;1.44]</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">5</td><td align="left">1.55 [1.35&#x02013;1.95]</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>LDL-C (mmol/l)</bold></td><td align="left">6</td><td align="left">2.93 [2.74&#x02013;3.96]</td><td align="left">2.93 [2.44&#x02013;3.00]</td><td align="left">0.7228</td><td align="left">2.93 [2.44&#x02013;3.00]</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">4</td><td align="left">2.30 [2.12&#x02013;2.70]</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>HDL-C (mmol/l)</bold></td><td align="left">6</td><td align="left">1.19 [1.17&#x02013;1.26]</td><td align="left">1.16 [1.14&#x02013;1.25]</td><td align="left">0.9997</td><td align="left">1.16 [1.13&#x02013;1.17]</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">5</td><td align="left">1.03 [0.75&#x02013;1.20]</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Creatinine (&#x000b5;mol/l)</bold></td><td align="left">5</td><td align="left">76.9 [59.7&#x02013;97.0]</td><td align="left">104.8 [89.6&#x02013;117.9]</td><td align="left">0.2796</td><td align="left">99.1 [84.7&#x02013;123.0]</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">3</td><td align="left">97.3 [96.0&#x02013;159.2]</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>GFR (ml/min/1.73m</bold><sup><bold>2</bold></sup><bold>)</bold></td><td align="left">4</td><td align="left">92.3 [90.7&#x02013;94.0]</td><td align="left">68.8 [61.2&#x02013;82.2]</td><td align="left">*</td><td align="left">65.1 [61.1&#x02013;74.9]</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left" colspan="11"><bold>Blood pressure</bold></td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>SBP, mm Hg</bold></td><td align="left">7</td><td align="left">124 [117&#x02013;124]</td><td align="left">127 [117&#x02013;131]</td><td align="left">0.9938</td><td align="left">127 [116&#x02013;130]</td><td align="left">126 [119&#x02013;133]</td><td align="left">&#x02013;*</td><td align="left">5</td><td align="left">127 [121&#x02013;140]</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>DBP, mm Hg</bold></td><td align="left">6</td><td align="left">70 [68&#x02013;72]</td><td align="left">72 [63&#x02013;77]</td><td align="left">*</td><td align="left">73 [63&#x02013;77]</td><td align="left">69 [67&#x02013;72]</td><td align="left">&#x02013;*</td><td align="left">5</td><td align="left">76 [73&#x02013;80]</td></tr><tr><td align="left" colspan="11"><bold>Cardiac function</bold></td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>LVEF, %</bold></td><td align="left">12</td><td align="left">59.8 [59.0&#x02013;61.8]</td><td align="left">32.0 [20.1&#x02013;39.9]</td><td align="left">0.0001</td><td align="left">31.0 [30.0&#x02013;33.5]</td><td align="left">65.0 [59.8&#x02013;70.1]</td><td align="left">&#x02013;*</td><td align="left">4</td><td align="left">59.5 [48.4&#x02013;65.7]</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>LVEDD, mm</bold></td><td align="left">4</td><td align="left">47.2 [46.0&#x02013;48.4]</td><td align="left">62.0 [59.1&#x02013;66.0]</td><td align="left">*</td><td align="left">62.0 [59.1&#x02013;66.0]</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left" colspan="2"><bold>Comorbidities/etiologies, yes (%)</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Atrial fibrillation</bold></td><td align="left">4</td><td align="left">&#x02013;</td><td align="left">308/1241 (25%)</td><td align="left">&#x02013;</td><td align="left">308/1241 (25%)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">2</td><td align="left">113/418 (27%)</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>COPD</bold></td><td align="left">4</td><td align="left">&#x02013;</td><td align="left">207/1159 (18%)</td><td align="left">&#x02013;</td><td align="left">207/1159 (18%)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Diabetes</bold></td><td align="left">12</td><td align="left">183/400 (46%)</td><td align="left">674/2077 (32%)</td><td align="left">0.0001</td><td align="left">636/1876 (35%)</td><td align="left">38/201 (19%)</td><td align="left">0.0001</td><td align="left">6</td><td align="left">801/3828 (21%)</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Hypertension</bold></td><td align="left">12</td><td align="left">227/400 (57%)</td><td align="left">1262/2081 (61%)</td><td align="left">0.1477</td><td align="left">1157/1876 (62%)</td><td align="left">101/201 (50%)</td><td align="left">0.0018</td><td align="left">4</td><td align="left">599/856 (70%)</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Ischemic etiology</bold></td><td align="left">3</td><td align="left">&#x02013;</td><td align="left">607/1241 (49%)</td><td align="left">&#x02013;</td><td align="left">607/1241 (49%)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">2</td><td align="left">244/520 (47%)</td></tr><tr><td align="left" colspan="11"><bold>Therapeutic strategies, yes (%)</bold></td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>ACE inhibitors</bold></td><td align="left">3</td><td align="left">&#x02013;</td><td align="left">1035/1326 (78%)</td><td align="left">&#x02013;</td><td align="left">1035/1326 (78%)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">4</td><td align="left">618/892 (69%)</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>ARB inhibitors</bold></td><td align="left">3</td><td align="left">&#x02013;</td><td align="left">295/1326 (22%)</td><td align="left">&#x02013;</td><td align="left">295/1326 (22%)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">2</td><td align="left">326/336 (97%)</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Beta-blockers</bold></td><td align="left">5</td><td align="left">&#x02013;</td><td align="left">1122/1486 (75%)</td><td align="left">&#x02013;</td><td align="left">1122/1486 (75%)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">2</td><td align="left">276/336 (82%)</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Diuretics</bold></td><td align="left">5</td><td align="left">&#x02013;</td><td align="left">1242/1486 (84%)</td><td align="left">&#x02013;</td><td align="left">1242/1486 (84%)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">2</td><td align="left">170/336 (51%)</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Cardiac glycosides</bold></td><td align="left">3</td><td align="left">&#x02013;</td><td align="left">428/1293 (33%)</td><td align="left">&#x02013;</td><td align="left">428/1293 (33%)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left" colspan="2">&#x02009;&#x02009;&#x02009;&#x02009;<bold>Statins</bold></td><td align="left">2</td><td align="left">&#x02013;</td><td align="left">221/340 (65%)</td><td align="left">&#x02013;</td><td align="left">221/340 (65%)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">5</td><td align="left">753/1065 (71%)</td></tr></tbody></table><table-wrap-foot><p>The data of continuous variables presented as median with interquartile range (IQR). The binary variables are presented as percentages. <italic>p</italic> value considered significant, when&#x02009;&#x0003c;&#x02009;0.05</p><p><italic>Abbreviations</italic>: <italic>HF </italic>heart failure, <italic>HFrEF</italic> heart failure with reduced ejection fraction, <italic>HFpEF</italic> heart failure with preserved ejection fraction, <italic>BMI</italic> body mass index, <italic>NT-proBNP</italic> the N-terminal prohormone of brain natriuretic peptide, <italic>BNP</italic> brain natriuretic peptide, <italic>LVEF</italic> left ventricle ejection fraction, <italic>NYHA</italic> New York Heart Association, <italic>LDL-C</italic> low-density lipoprotein cholesterol, <italic>HDL-C</italic> high-density lipoprotein cholesterol, <italic>GFR</italic> glomerular filtration rate, <italic>SBP</italic> systolic blood pressure, <italic>DBP</italic> diastolic blood pressure, <italic>COPD</italic> chronic obstructive pulmonary disease, <italic>LVEDD </italic>left ventricular end-diastolic diameter, <italic>ACE</italic> angiotensin converting enzyme, <italic>ARB</italic> angiotensin II receptor blocker, <italic>RAAS</italic> renin&#x02013;angiotensin&#x02013;aldosterone system</p><p>*<italic>p</italic> value was not calculated due to presence of only two numeric value in at least one group of comparison</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec16"><title>Aggregate data meta-analysis</title><p id="Par47">Nineteen publications [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] were included in the aggregated prognostic meta-analysis comprising a total of 5553 participants (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) based on the presence of effect size data. We performed data extraction of individual non-adjusted/adjusted HR and non-adjusted/adjusted OR from all 19 studies [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] (Additional file 1: Table S3). Data were stratified based on reported outcomes in included studies. These included HF composite endpoint, HF hospitalization and/or cardiovascular (CV) death, all-cause death and CV death, combined endpoints, and HF incidence [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Prognostic and predictive performance of miRNAs in HF patients (1715 patients from eight studies) and population-based cohorts (3330 participants from six studies). MicroRNA-specific aHR/aOR were pooled by DerSimonian-Laird random effect model. The dashed line shows the pooled effect estimate. The solid horizontal line depicts 95% CI. The squares indicate weighted effect estimates of each miRNA. The diamond represents the overall effect estimate with 95% CI in the random effect model</p></caption><graphic xlink:href="12916_2025_4238_Fig2_HTML" id="MO3"/></fig></p></sec><sec id="Sec17"><title>HF</title><sec id="Sec18"><title>HF-related outcomes</title><p id="Par48">Cumulative data from 20 miRNAs (let-7i-5p, miR-15a, miR-16, miR-20a, miR-21, miR-23a, miR-29a, miR-30d, miR-30e, miR-93, miR-101, miR-106b, miR-122, miR-129-5p, miR-132, miR-133a, miR-144, miR-145-5p, miR-423, and miR-590-3p) predicted HF-related outcomes with an overall aHR of 1.09 [1.00&#x02013;1.19] (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). All-cause death or CV death could be predicted significantly by 6 miRNAs (miR-132-3p, miR-122-5p, miR-423-5p, miR-145-5p, miR-590-5p, and miR-129-5p) with an aHR of 1.27 [1.08&#x02013;1.48]. However, the heterogeneity for all-cause or CV death was high based on <italic>I</italic><sup>2</sup> test (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). Moreover, miR-21-5p, miR-132-3p, miR-122-5p, let-7i-5p, miR-29a-5p, and miR-133a-3p were unable to predict HF hospitalization or CV death (aHR of 1.10 [0.90&#x02013;1.35]). The overall data changed when a leave-one-out test using aHR was conducted (Additional file 1: Fig. S2A). MiR-145-5p, miR-133a, miR-590-3p, and miR-129-5p reported by four studies showed publication bias (Additional file 1: Fig. S2B). Sensitivity analysis showed significant changes in the overall effect size upon removal of miR-145-5p, miR-133a, miR-590-3p, and miR-129-5p (aHR of 1.05 [0.97&#x02013;1.13]).</p></sec><sec id="Sec19"><title>HF incidence</title><p id="Par49">Cumulative data derived from 10 miRNAs (miR-17-5p, miR-20a-5p, miR-20b-5p, miR-23a-3p, miR-26a-5p, miR-26b-5p, miR-93-5p, miR-106b-5p, miR-126-5p, and miR-126-3p) showed significant association between miRNA plasma levels and HF incidence in the general population (aHR of 0.90 [0.85&#x02013;0.94]) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B). Moreover, dysregulation of a set of 19 miRNAs (let-7b-5p, miR-20a-5p, miR-21-5p, miR-23a-3p, miR-27b-3p, miR-30b-5p, miR-34a, miR-106b-5p, miR-107, miR-122-5p, miR-133a, miR-133b, miR-148b-3p, miR-206, miR-208b, miR-210-3p, miR-221-3p, miR-326, and miR-499-5p) in the patient cohorts, including MI with risk of HF, predicts an increased risk of HF incidence with effect size of 1.42 [1.16&#x02013;1.75]. The heterogeneity analysis showed an acceptable level with <italic>I</italic><sup>2</sup> of 69% (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B). Leave-one-out analysis showed the contribution of different miRNAs in the overall effect size (Additional file 1: Fig. S2D).</p></sec></sec><sec id="Sec20"><title>HFrEF and HFpEF</title><p id="Par50">We then performed a subgroup analysis considering both HFrEF and HFpEF. Overall, circulating miRNAs (let-7i-5p, miR-15a, miR-16, miR-20a, miR-21, miR-23a, miR-29a, miR-30d, miR-30e, miR-93, miR-101, miR-106b, miR-122, miR-129-5p, miR-132, miR-133a, miR-144, miR-145-5p, miR-423, and miR-590-3p) showed significant predictive value (aHR 1.11 [1.01&#x02013;1.21]) in HFrEF patients. However, heterogeneity was considered in the acceptable range with <italic>I</italic><sup>2</sup> of 71.60% (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A and Additional file 1: Fig. S5A). The leave-one-out method showed that all individual miRNAs significantly contribute to the overall predictive value (Additional file 1: Figs. S4 and S5).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Prognostic performance of miRNAs in HFrEF and HFpEF patients (1639 HFrEF patients from seven studies and 201 HFpEF patients from two studies). MicroRNA-specific aHR and/or HR were pooled by DerSimonian-Laird random effect model and inverse variance fixed effect model. The dashed line shows the pooled effect estimate. The solid horizontal line showed the 95% CI. The squares indicate weighted effect estimates of each miRNA. The diamond represents the overall effect estimate with 95% CI in the random effect model and fixed effect model</p></caption><graphic xlink:href="12916_2025_4238_Fig3_HTML" id="MO4"/></fig></p><p id="Par51">In patients with HFpEF, pooling prognostic data from three miRNAs (miR-19a, miR-21, and miR-186) predicted HF hospitalization and/or all-cause death with an HR/aHR of 0.93 [0.87&#x02013;0.99] with heterogeneity of <italic>I</italic><sup>2</sup>&#x02009;=&#x02009;90% (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B). The leave-one-out test showed a significant contribution of each miRNA in the overall results (Additional file 1: Fig. S6B).</p></sec><sec id="Sec21"><title>Kaplan&#x02013;Meier-based meta-analysis</title><p id="Par52">KM-based meta-analysis was performed on data available from 12 studies [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>] comprising 5064 participants (Additional file 1: Table S3). In the included studies, various outcomes (HF incidence, all-cause death, and CV death) were documented, with patients categorized into different groups (high- vs. low-risk group) based on specific cut-off values for miRNA expression levels.</p><sec id="Sec22"><title>All-cause death</title><p id="Par53">All-cause death among HF patients was predicted (HR 1.43 [1.22&#x02013;1.68]) by pooling data from 10 miRNAs (miR-19a-3p, miR-27a-3p, miR-122-5p, miR-129-5p, miR-132, miR-145-5p, miR-182-5p, miR-186-5p, miR-423-5p, and miR-590-3p). Log-rank test demonstrated a significant potential of miRNAs in risk stratification of patients (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Additional file 1: Fig. S7A and D).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>MiRNA prognostic panels for risk stratification of HF incidence and HF-related outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="2"><bold>HF incidence</bold></th><th align="left" colspan="2"><bold>All-cause death</bold></th><th align="left" colspan="2"><bold>CV death</bold></th></tr><tr><th align="left"><bold>Low-risk</bold></th><th align="left"><bold>High-risk</bold></th><th align="left"><bold>Low-risk</bold></th><th align="left"><bold>High-risk</bold></th><th align="left"><bold>Low-risk</bold></th><th align="left"><bold>High-risk</bold></th></tr></thead><tbody><tr><td align="left"><bold>No. of miRNAs</bold></td><td align="left" colspan="2">9<sup>*</sup></td><td align="left" colspan="2">10<sup>#</sup></td><td align="left" colspan="2">3<sup>&#x000a5;</sup></td></tr><tr><td align="left"><bold>No. of studies</bold></td><td align="left" colspan="2">2</td><td align="left" colspan="2">8</td><td align="left" colspan="2">2</td></tr><tr><td align="left"><bold>No. of measured effects</bold></td><td align="left">4490</td><td align="left">4314</td><td align="left">972</td><td align="left">539</td><td align="left">844</td><td align="left">485</td></tr><tr><td align="left"><bold>No. of measured events</bold></td><td align="left">198</td><td align="left">388</td><td align="left">392</td><td align="left">280</td><td align="left">115</td><td align="left">155</td></tr><tr><td align="left"><bold>Outcome rate, % (SEM)</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>1-y follow-up</bold></td><td align="left">1.4 (0.2)</td><td align="left">3.4 (0.3)</td><td align="left">7.3 (0.7)</td><td align="left">10.8 (1.1)</td><td align="left">5.3 (0.7)</td><td align="left">7.2 (1.0)</td></tr><tr><td align="left"><bold>3-y follow-up</bold></td><td align="left">2.5 (0.2)</td><td align="left">5.2 (0.3)</td><td align="left">19.7 (1.3)</td><td align="left">26.4 (1.8)</td><td align="left">13.5 (1.4)</td><td align="left">18.9 (1.8)</td></tr><tr><td align="left"><bold>5-y follow-up</bold></td><td align="left">3.4 (0.3)</td><td align="left">7.0 (0.4)</td><td align="left">28.4 (1.7)</td><td align="left">36.3 (2.2)</td><td align="left">17.6 (1.7)</td><td align="left">35.7 (2.5)</td></tr><tr><td align="left"><bold>At maximum follow-up</bold></td><td align="left">5.3 (0.4)</td><td align="left">11.4 (0.7)</td><td align="left">72.3 (2.5)</td><td align="left">77.3 (4.3)</td><td align="left">17.9 (1.7)</td><td align="left">36.4 (2.5)</td></tr><tr><td align="left"><bold>Hazard ratio (95% CI)</bold></td><td align="left" colspan="2">2.04 (1.73&#x02013;2.40)</td><td align="left" colspan="2">1.43 (1.22&#x02013;1.68)</td><td align="left" colspan="2">1.85 (1.45&#x02013;2.36)</td></tr><tr><td align="left"><bold>Log-rank (Mantel-Cox) test (</bold><bold><italic>p</italic></bold>
<bold>value)</bold></td><td align="left" colspan="2">&#x02009;&#x0003c;&#x02009;0.0001</td><td align="left" colspan="2">&#x02009;&#x0003c;&#x02009;0.0001</td><td align="left" colspan="2">&#x02009;&#x0003c;&#x02009;0.0001</td></tr></tbody></table><table-wrap-foot><p>Hazard ratio (95% CI)&#x02009;=&#x02009;high-risk/low-risk, <italic>SEM</italic> standard error of the mean. <italic>p</italic> value considered significant when&#x02009;&#x0003c;&#x02009;0.05</p><p>*&#x02009;=&#x02009;miR-17-5p, miR-20a-5p, miR-106b-5p, miR-21, miR-23, miR-27, miR-122, miR-210, and miR-221</p><p>#&#x02009;=&#x02009;miR-19a-3p, miR-27a-5p, miR-122-5p, miR-129-5p, miR-132-3p, miR-145-5p, miR-182-5p, miR-186-5p, miR-423-5p, and miR-590-3p</p><p>&#x000a0;&#x000a5;&#x02009;=&#x02009;miR-122-5p, miR-132-3p, and miR-423-5p</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec23"><title>CV death</title><p id="Par54">Three miRNAs (miR-122-5p, miR-132-3p, and miR-423-5p) stratified HF patients in risk categories (log-rank <italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.0001) and a significant prognostic value for CV death was observed (HR 1.85 [1.45&#x02013;2.36]) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Additional file 1: Fig. S7B and D).</p></sec><sec id="Sec24"><title>HF incidence</title><p id="Par55">The pooled data from nine miRNAs (miR-17-5p, miR-20a-5p, miR-21, miR-23, miR-27, miR-106b-5p, miR-122, miR-210, and miR-221) identified by individual data reconstruction was able to stratify patients into low- vs. high-risk of HF incidence (log-rank <italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.0001) with overall HR of 2.04 [1.73&#x02013;2.40] (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Additional file 1: Fig. S7C and D).</p></sec></sec><sec id="Sec25"><title>Multi-miRNA panels with prognostic and predictive value for HF</title><p id="Par56">We performed univariate Cox regression analysis on reconstructed IPD for three different outcomes in HFrEF (HF hospitalization, all-cause death, and CV death), one in HFpEF (all-cause death), and HF incidence. Thereafter, miRNAs with significant predictive value were selected based on AIC and <italic>C</italic>-statistics for each outcome.</p><sec id="Sec26"><title>HFrEF</title><p id="Par57">A panel of 4 miRNAs (miR-27a-3p, miR-129-5p, miR-145-5p, and miR-590-3p) was significantly associated with all-cause death (HR 4.26 [2.68&#x02013;6.76]). <italic>C</italic>-statistics showed the significant potential of these miRNAs in risk stratification of patients (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, and Additional file 1: Fig. S8A). MiR-122-5p and miR-423-5p predicted CV death (HR 3.61 [2.67&#x02013;4.87]) and stratified patients into low- vs. high-risk groups (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, and Additional file 1: Fig. S8A and B).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Prognostic and risk stratification potentials of identified panels of miRNAs in HFrEF and HFpEF patients. Panel of 4 miRNAs (miR-27a-3p, miR-129-5p, miR-145-5p, and miR-590-3p) for all-cause death prediction and risk stratification of HFrEF patients (<bold>A</bold>), panel of 2 miRNAs (miR-122-5p and miR-423-5p) for CV death prediction and risk stratification of HFrEF patients (<bold>B</bold>), panel of eight miRNAs (miR-17-5p, miR-20a-5p, miR-21-5p, miR-23a-3p, miR-27b-3p, miR-106b-5p, miR-210-3p, and miR-221-3p) for prediction of HF incidence (<bold>C</bold>), and miR-19a-3p for all-cause death prediction and risk stratification of HFpEF patients (<bold>D</bold>). HR presented as high-risk/low-risk</p></caption><graphic xlink:href="12916_2025_4238_Fig4_HTML" id="MO5"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>Prognostic value of individual MiRNAs for HF incidence and HF-related outcomes in population-based cohorts and heart failure (HFrEF and HFpEF) patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" rowspan="3"><bold>Biomarker</bold></th><th align="left" rowspan="3"><bold>miRBase ID</bold></th><th align="left" colspan="6"><bold>Univariate analysis</bold></th></tr><tr><th align="left" rowspan="2"><bold>HR (95% CI)</bold></th><th align="left" colspan="3"><bold>AIC</bold></th><th align="left" rowspan="2"><bold>LRT (</bold><italic>p</italic> value)</th><th align="left" rowspan="2"><bold><italic>C</italic></bold><bold>-statistics (AUC)</bold></th></tr><tr><th align="left"><bold>Empty model</bold></th><th align="left"><bold>Selected model</bold></th><th align="left"><bold>Wald test (</bold><italic>p</italic> value)</th></tr></thead><tbody><tr><td align="left" rowspan="10"><bold>Population-based cohort</bold></td><td align="left" colspan="8"><bold>HF incidence</bold></td></tr><tr><td align="left">miR-106b-5p</td><td align="left">MIMAT0000680</td><td char="&#x02013;" align="char">1.43 (1.32&#x02013;1.55)</td><td align="left">33,358</td><td align="left">33,288</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.0001</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.0001</td><td char="." align="char">0.5382</td></tr><tr><td align="left">miR-20a-5p</td><td align="left">MIMAT0000075</td><td char="&#x02013;" align="char">1.18 (1.08&#x02013;1.27)</td><td align="left">33,125</td><td align="left">33,111</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.0001</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.0001</td><td char="." align="char">0.5334</td></tr><tr><td align="left">miR-17-5p</td><td align="left">MIMAT0000070</td><td char="&#x02013;" align="char">1.52 (1.40&#x02013;1.66)</td><td align="left">33,029</td><td align="left">32,933</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.0001</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;0.0001</td><td char="." align="char">0.5435</td></tr><tr><td align="left">miR-27b-3p</td><td align="left">MIMAT0000419</td><td char="&#x02013;" align="char">2.08 (1.13&#x02013;3.99)</td><td align="left">472</td><td align="left">468.8</td><td char="." align="char">0.0210</td><td char="." align="char">0.0176</td><td char="." align="char">0.5853</td></tr><tr><td align="left">miR-122-5p</td><td align="left">MIMAT0000421</td><td char="&#x02013;" align="char">1.20 (0.66&#x02013;2.22)</td><td align="left">445</td><td align="left">446.2</td><td char="." align="char">0.5361</td><td char="." align="char">0.5355</td><td char="." align="char">0.5284</td></tr><tr><td align="left">miR-210-3p</td><td align="left">MIMAT0000267</td><td char="&#x02013;" align="char">2.89 (1.53&#x02013;5.85)</td><td align="left">456</td><td align="left">447.3</td><td char="." align="char">0.0017</td><td char="." align="char">0.0008</td><td char="." align="char">0.6251</td></tr><tr><td align="left">miR-221-3p</td><td align="left">MIMAT0000278</td><td char="&#x02013;" align="char">2.71 (1.42&#x02013;5.49)</td><td align="left">442</td><td align="left">434.6</td><td char="." align="char">0.0034</td><td char="." align="char">0.0019</td><td char="." align="char">0.6135</td></tr><tr><td align="left">miR-21-5p</td><td align="left">MIMAT0000076</td><td char="&#x02013;" align="char">5.33 (2.52&#x02013;13.09)</td><td align="left">475</td><td align="left">454.7</td><td char="." align="char">0.0001</td><td char="." align="char">0.0001</td><td char="." align="char">0.6718</td></tr><tr><td align="left">miR-23a-3p</td><td align="left">MIMAT0000078</td><td char="&#x02013;" align="char">5.53 (2.60&#x02013;13.63)</td><td align="left">419</td><td align="left">398.5</td><td char="." align="char">0.0001</td><td char="." align="char">0.0001</td><td char="." align="char">0.6820</td></tr><tr><td align="left" rowspan="15"><bold>HFrEF</bold></td><td align="left" colspan="8"><bold>HF hospitalization</bold></td></tr><tr><td align="left">miR-132-3p</td><td align="left">MIMAT0000426</td><td char="&#x02013;" align="char">0.74 (0.53&#x02013;1.00)</td><td align="left">2298</td><td align="left">2296</td><td char="." align="char">0.0597</td><td char="." align="char">0.0549</td><td char="." align="char">0.5310</td></tr><tr><td align="left" colspan="8"><bold>All-cause death</bold></td></tr><tr><td align="left">miR-27a-3p</td><td align="left">MIMAT0004501</td><td char="&#x02013;" align="char">6.51 (1.54&#x02013;27.58)</td><td align="left">70</td><td align="left">66</td><td char="." align="char">0.0081</td><td char="." align="char">0.0129</td><td char="." align="char">0.6870</td></tr><tr><td align="left">miR-129-5p</td><td align="left">MIMAT0000242</td><td char="&#x02013;" align="char">5.56 (1.84&#x02013;23.92)</td><td align="left">145</td><td align="left">137</td><td char="." align="char">0.0064</td><td char="." align="char">0.0013</td><td char="." align="char">0.6811</td></tr><tr><td align="left">miR-145-5p</td><td align="left">MIMAT0000437</td><td char="&#x02013;" align="char">2.71 (1.22&#x02013;6.63)</td><td align="left">215</td><td align="left">211</td><td char="." align="char">0.0187</td><td char="." align="char">0.0138</td><td char="." align="char">0.6291</td></tr><tr><td align="left">miR-590-3p</td><td align="left">MIMAT0004801</td><td char="&#x02013;" align="char">2.58 (1.11&#x02013;6.69)</td><td align="left">194</td><td align="left">191</td><td char="." align="char">0.0343</td><td char="." align="char">0.0260</td><td char="." align="char">0.6185</td></tr><tr><td align="left">miR-182-5p</td><td align="left">MIMAT0000259</td><td char="&#x02013;" align="char">2.46 (0.97&#x02013;7.00)</td><td align="left">150</td><td align="left">148</td><td char="." align="char">0.0683</td><td char="." align="char">0.0577</td><td char="." align="char">0.6146</td></tr><tr><td align="left">miR-122-5p</td><td align="left">MIMAT0000421</td><td char="&#x02013;" align="char">1.00 (0.27&#x02013;3.59)</td><td align="left">76</td><td align="left">78</td><td char="." align="char">0.9999</td><td char="." align="char">0.9999</td><td char="." align="char">0.5000</td></tr><tr><td align="left">miR-423-5p</td><td align="left">MIMAT0004748</td><td char="&#x02013;" align="char">1.00 (0.63&#x02013;1.57)</td><td align="left">729</td><td align="left">731</td><td char="." align="char">0.9999</td><td char="." align="char">0.9999</td><td char="." align="char">0.5000</td></tr><tr><td align="left">miR-132-3p</td><td align="left">MIMAT0000426</td><td char="&#x02013;" align="char">0.82 (0.56&#x02013;1.19)</td><td align="left">1613</td><td align="left">1614</td><td char="." align="char">0.3173</td><td char="." align="char">0.3118</td><td char="." align="char">0.5155</td></tr><tr><td align="left" colspan="8"><bold>CV death</bold></td></tr><tr><td align="left">miR-122-5p</td><td align="left">MIMAT0000421</td><td char="&#x02013;" align="char">4.51 (2.75&#x02013;7.82)</td><td align="left">942</td><td align="left">903</td><td char="." align="char">0.0001</td><td char="." align="char">0.0001</td><td char="." align="char">0.6676</td></tr><tr><td align="left">miR-423-5p</td><td align="left">MIMAT0004748</td><td char="&#x02013;" align="char">2.94 (1.86&#x02013;4.82)</td><td align="left">843</td><td align="left">823</td><td char="." align="char">0.0001</td><td char="." align="char">0.0001</td><td char="." align="char">0.6248</td></tr><tr><td align="left">miR-132-3p</td><td align="left">MIMAT0000426</td><td char="&#x02013;" align="char">0.65 (0.40&#x02013;1.00)</td><td align="left">1245</td><td align="left">1244</td><td char="." align="char">0.0614</td><td char="." align="char">0.0536</td><td char="." align="char">0.5380</td></tr><tr><td align="left" rowspan="3"><bold>HFpEF</bold></td><td align="left" colspan="8"><bold>All-cause death</bold></td></tr><tr><td align="left">miR-19a-3p</td><td align="left">MIMAT0004490</td><td char="&#x02013;" align="char">2.27 (1.34&#x02013;3.67)</td><td align="left">733</td><td align="left">726</td><td char="." align="char">0.0014</td><td char="." align="char">0.0031</td><td char="." align="char">0.5557</td></tr><tr><td align="left">miR-186-5p</td><td align="left">MIMAT0000456</td><td char="&#x02013;" align="char">1.92 (1.12&#x02013;3.12)</td><td align="left">708</td><td align="left">705</td><td char="." align="char">0.0118</td><td char="." align="char">0.0183</td><td char="." align="char">0.5468</td></tr></tbody></table><table-wrap-foot><p>Wald and likelihood ratio test considered significant when<italic> p </italic>value&#x02009;<italic>&#x0003c;&#x02009;0.05</italic></p><p><italic>Abbreviations</italic>: <italic>AIC</italic> Akaike information criterion, <italic>HF&#x000a0;</italic>heart failure, <italic>LRT&#x000a0;</italic>likelihood ratio test</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec27"><title>HF incidence</title><p id="Par58">A panel of eight miRNAs (miR-17-5p, miR-20a-5p, miR-21, miR-23, miR-27, miR-106b-5p, miR-210, and miR-221) was associated with increased HF incidence (HR of 2.14 [2.01&#x02013;2.27]). <italic>C</italic>-statistics showed significant discriminatory potential of these miRNAs (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, and Additional file 1: Fig. S8B).</p></sec><sec id="Sec28"><title>HFpEF</title><p id="Par59">Based on selection criteria, miR-19a-3p was the best predictor of all-cause death (HR 2.23 [1.16&#x02013;4.27]) with significant risk stratification potential (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>D, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, and Additional file 1: Fig. S8C and D).</p></sec></sec></sec><sec id="Sec29"><title>Discussion</title><p id="Par60">This study addressed the performance of circulating miRNAs in predicting HF incidence, CV death, and all-cause death in HFrEF or HFpEF patients. An aggregated meta-analysis followed by reconstructed IPD analysis based on published KM was deployed to limit publication bias and minimize the influence of study heterogeneity. Data analysis from 5064 patients allowed the identification of a panel containing four miRNAs (miR-27a-3p, miR-129-5p, miR-145-5p, and miR-590-3p) predicting the risk of all-cause death in HFrEF patients and a panel of eight miRNAs (miR-17-5p, miR-20a-5p, miR-21, miR-23, miR-27, miR-106b-5p, miR-210, and miR-221) predicting HF incidence. In addition, miR-19a-3p predicted all-cause death in HFpEF patients.</p><p id="Par61">The prevalence of HF is continuously increasing, adding economic pressure and psychological challenges to healthcare systems around the world [<xref ref-type="bibr" rid="CR40">40</xref>]. Although currently available tools provide accurate HF diagnoses, they often fail in early detection of subclinical states and are unable to provide information about long-term outcomes, thereby preventing personalized treatment [<xref ref-type="bibr" rid="CR5">5</xref>]. A meta-analysis reported that increased BNP levels of 100 pg/ml were associated with 14% elevated mortality in HF patients with either acute or chronic HF [<xref ref-type="bibr" rid="CR41">41</xref>]. However, the etiological complexity of HF renders the use of a single prognostic biomarker insufficient [<xref ref-type="bibr" rid="CR5">5</xref>]. We previously described panels of miRNAs that can be used as potential diagnostic biomarkers for HFpEF and HFrEF patients [<xref ref-type="bibr" rid="CR15">15</xref>]. Combining multi-miRNA panels with conventional biomarkers (NT-proBNP and BNP) improved diagnostic performance [<xref ref-type="bibr" rid="CR15">15</xref>]. In the present study, we focused on miRNA panels with prognostic value for both HFrEF and HFpEF patients.</p><sec id="Sec30"><title>Prognostic value of circulating miRNAs in heart failure</title><p id="Par62">Overall, our data showed that fluctuations in circulating levels of miRNA are associated with a 42% increased risk of HF incidence in the population with a risk of HF development. Moreover, we found that altered miRNA levels are associated with a 27% increase in all-cause and CV death. In line with our results, Cao et al. [<xref ref-type="bibr" rid="CR42">42</xref>] reported that miRNA expression levels are associated with 48% increased mortality during acute myocardial infarction. Therefore, adding miRNA expression levels to currently recommended prognostic biomarkers, including cTnT, BNP, and NT-proBNP, may yield better and more robust outcome predictions for HF patients. Furthermore, the essential roles of miRNAs in the pathophysiology of HF associated with cardiac (i.e., myocyte hypertrophy, fibrosis, contractility, angiogenesis, apoptosis, arrhythmia) and non-cardiac phenotypes [<xref ref-type="bibr" rid="CR43">43</xref>] make them attractive candidates for the development of diagnostic tools to risk-stratify patients and aid in tailored treatments.</p></sec><sec id="Sec31"><title>Data heterogeneity</title><p id="Par63">The high heterogeneity observed in the present study is in line with past miRNA-based meta-analyses [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR42">42</xref>] and can be explained by the use of different detection methods, varying inclusion/exclusion criteria, HF type, outcome definition, and miRNAs included. To circumvent the lack of data for each specific miRNA, we stratified studies based on reported outcomes, which led to lesser heterogeneity in HF composite endpoint as well as HF hospitalization and/or CV death outcomes. Additionally, the qualitative analysis (QUIPS questionnaire) revealed a low risk of bias for study design. The homogenous nature of the data enabled us to extract and pool the KM-based IPD. Our KM-based IPD analyses showed that miRNAs can stratify patients into low- vs. high-risk categories, based on specific cut-offs. Pooling IPD data from the expression levels of nine miRNAs showed 4% more HF development in high-risk patients compared to low-risk patients during a 5-year follow-up. Compared to low-risk patients, our data showed a 19% increase in CVD-related deaths by pooling data from three miRNAs in high-risk patients. Despite being statistically significant, there was only an 8% difference between low- and high-risk patients in all-cause death at 5-year follow-up. Overall, our KM-based IPD analysis provides complementary data on patient stratification and corroborates the aggregated data meta-analysis results.</p></sec><sec id="Sec32"><title>MiRNA prognostic and predictive panels for HF incidence and HF-related outcomes</title><p id="Par64">In the current study, prognostic data from 64 miRNAs were gathered. Among these, a set of four miRNAs were associated with all-cause death (miR-27a-3p, miR-129-5p, miR-145-5p, and miR-590-3p) with HR 4.259 (2.681&#x02013;6.764) and two with CV death (miR-122 and miR-423-5p) with HR 3.608 (2.671&#x02013;4.873) in HFrEF patients. In a clinical setting, Chang et al. [<xref ref-type="bibr" rid="CR20">20</xref>] showed that downregulation of miR-590-3p correlates negatively with BNP [<xref ref-type="bibr" rid="CR44">44</xref>]. However, there is no evidence regarding a correlation between serum and tissue levels of miR-590-3p to give more insight into the possible source of secretion. Based on our analysis, miR-27a-3p has the highest association with all-cause death. This is in agreement with a previous study on chronic HF patients showing that decreased miR-27a serum levels correlated with cardiac function and BNP levels [<xref ref-type="bibr" rid="CR37">37</xref>]. Interestingly, it has been demonstrated that miR-27a-3p can be absorbed by the heart [<xref ref-type="bibr" rid="CR45">45</xref>]. Our analyses also indicated the value of miR-129-5p and miR-145-5p in the prognostication of all-cause death in HFrEF. These two miRNAs correlate positively with EF [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] and are negatively correlated with NYHA classification [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Furthermore, miR-122-5p and miR-423-5p are associated with CV death in HFrEF patients. In line with this, Marques et al. [<xref ref-type="bibr" rid="CR45">45</xref>] observed that miR-122-5p can be released by the failing heart, and several other studies showed that miR-122-5p is upregulated in HF [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR46">46</xref>] and in acute coronary syndrome [<xref ref-type="bibr" rid="CR47">47</xref>]. Vogel and colleagues showed a negative correlation of miR-122-5p expression level with left ventricular EF and positive correlation with NYHA class [<xref ref-type="bibr" rid="CR35">35</xref>]. Recent studies on aortic valve stenosis patients corroborated the negative correlation between miR-122-5p and EF and reported a significant association with left ventricular function improvement [<xref ref-type="bibr" rid="CR47">47</xref>]. Several studies have shown the diagnostic potential of miR-423-5p in both acute and chronic HF [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. However, the prognostic performance of miR-423-5p is still under debate. The univariate Cox data from Bayes-Genis et al. [<xref ref-type="bibr" rid="CR7">7</xref>] showed an association between miR-423-5p expression level and both HF hospitalization and all-cause death in one cohort. Still, they failed to reproduce the results in a second cohort. On the other hand, in univariate and multivariate Cox regression, Stojkovic et al. [<xref ref-type="bibr" rid="CR34">34</xref>] reported a significant association of miR-423-5p expression level with both all-cause death and CV death.</p><p id="Par65">Other miRNAs have been implicated in the diagnosis and treatment of HFrEF patients. Circulating levels of miR-132 were increased in HF patients and may enhance risk prediction for HF hospitalization [<xref ref-type="bibr" rid="CR13">13</xref>]. Furthermore, results from a first-in-human phase Ib randomized, double-blinded, placebo-controlled clinical study indicated that the treatment was safe and well tolerated by patients, confirming its beneficial effects for HF [<xref ref-type="bibr" rid="CR50">50</xref>]. Additionally, the inhibition of cardiac miR-132 using a specific antisense oligonucleotide is currently being tested in chronic ischemic heart failure patients as part of the phase II HF-REVERT clinical trial (NCT05350969).</p><p id="Par66">In population-based cohorts, either general population or patient cohorts, the univariate analysis led to the identification of eight miRNAs (miR-17-5p, miR-20a-5p, miR-21, miR-23, miR-27, miR-210, miR-221, and miR-106b-5p) associated with HF incidence (HR 2.137 [1.806&#x02013;2.529]). Moreover, miR-19a for all-cause death (HR 2.229 [1.162&#x02013;4.273]) in HFpEF patients. The prognostic performance of miR-20a-5p has been investigated in post-infarction HF [<xref ref-type="bibr" rid="CR51">51</xref>], chronic thromboembolic pulmonary hypertension [<xref ref-type="bibr" rid="CR52">52</xref>], dilated cardiomyopathy [<xref ref-type="bibr" rid="CR53">53</xref>], ischemic cardiomyopathy [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>], atrial fibrillation [<xref ref-type="bibr" rid="CR55">55</xref>], myocardial remodeling, and chronic HF [<xref ref-type="bibr" rid="CR12">12</xref>]. Previous studies showed that lowered levels of miR-20a-5p are associated with increased incidence of HF [<xref ref-type="bibr" rid="CR12">12</xref>] and atrial fibrillation [<xref ref-type="bibr" rid="CR55">55</xref>]. Downregulation of miR-17-5p in either serum or plasma was previously reported in HF [<xref ref-type="bibr" rid="CR45">45</xref>] and acute coronary syndrome [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Absorption of miR-17-5p in the failing heart might explain the lower levels in the bloodstream [<xref ref-type="bibr" rid="CR45">45</xref>]. MiR-106b-5p was upregulated in two HF animal models and correlated positively with BNP level [<xref ref-type="bibr" rid="CR58">58</xref>]. MiR-106b-5p upregulation has also been reported in carotid artery syndrome [<xref ref-type="bibr" rid="CR59">59</xref>] and unstable angina [<xref ref-type="bibr" rid="CR60">60</xref>]. In the Framingham Heart Study, downregulation of miR-19a-3p was associated with all-cause mortality in HFpEF patients [<xref ref-type="bibr" rid="CR36">36</xref>]. On the other hand, miR-19a-3p was upregulated in dilated cardiomyopathy patients and was positively correlated with BNP [<xref ref-type="bibr" rid="CR61">61</xref>]. Whether these miRNAs functionally contribute to the development and progression of HFpEF remains to be thoroughly investigated.</p></sec></sec><sec id="Sec33"><title>Study strengths and limitations</title><p id="Par67">The current study has several strengths. First, we collected the largest amount of available evidence (5736 patient data) via a comprehensive search strategy and sophisticated quantitative analysis on the prognostic performance of circulating miRNA for HF patients. Second, the KM-based approach provides a more accurate estimation of survival data and corroborates the aggregated meta-analysis. Third, the exploratory approach of the pipeline reported here successfully provided robust evidence for the usefulness of panels of miRNAs with predictive and prognostic value. These findings have clear potential for translation into clinical application and improved outcomes for HF patients and HF incidence.</p><p id="Par68">We acknowledge that, although an extensive literature search was performed, one study [<xref ref-type="bibr" rid="CR12">12</xref>] provided almost half of the patients for both KM-based IPD analysis and aggregated meta-analysis, thereby restricting data generalization. It is important to note that reconstruction of IPD relies on the resolution of KM curves reported in the studies, which limits its accuracy. The KM-based IPD analysis was limited to univariate Cox analysis as confounding factors (e.g., age, BMI, gender) were unavailable. Additionally, the aggregated meta-analysis was limited to reported data adjusted for different risk factors. Due to the nature of our study, the panels of miRNAs have been selected based on reported outcomes, so further investigation is required to understand the global predictors of complications and poor prognosis. The data presented showed partially high heterogeneity in some outcomes, mainly due to different miRNAs being reported in individual studies with different analytical methods. The larger heterogeneity could also be explained by the fact that the data presented by some studies were derived from pre-selected panels and warrants caution in interpretation of results. Moreover, due to insufficient data for HF incidence in terms of effect size, we combined the hazard ratio and odds ratio to perform the meta-analysis. This can in part explain the slightly higher heterogeneity. Additionally, due to the nature of our study, we were not able to consider the study weight as a criterion for miRNA panel selection. Also, we combined adjusted and non-adjusted hazard ratios in HFpEF, which can also lead to increase heterogeneity. Lastly, evaluation of a likely pooled effect of miRNAs with already established biomarkers (such as BNP) was not performed due to insufficient information provided in the included studies.</p></sec><sec id="Sec34"><title>Conclusions</title><p id="Par69">We identified four independent panels of circulating miRNAs that predict the risk of serious complications caused by HFrEF and HFpEF, as well as HF incidence. The performed meta-analysis advances current knowledge by bringing consensus to the usefulness of circulating miRNAs as prognostic biomarkers, showcasing a robust pipeline for prioritization of highly predictive miRNAs for complications associated with HF. Based on these findings, we expect that the combination of miRNA signatures with conventional biomarkers holds promising prognostic potential for HF and may lead to improvements in precision medicine. More studies are required to develop a reliable scoring system for HF, which integrates multi-panels of conventional and novel biomarkers with imaging tools and clinical parameters to better predict disease complications at the individual patient level.</p></sec><sec id="Sec118" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4238_MOESM1_ESM.docx"><caption><p>Additional file 1: Supplementary tables and figures. Fig. S1 Risk of bias assessments of the included studies using QUIPS tool. Fig. S2 Funnel plot (A) and leave-one-out (B) analysis of contribution of each miRNA in overall effect estimate of aHR for heart failure patients. Funnel plot (C) and leave-one-out (D) analysis of contribution of each miRNA in overall effect estimate of aHR for HF incidence. Fig. S3 Forest plot of pooled HR (A), funnel plot (B), and leave-one-out (C) analysis of contribution of each miRNA in overall effect estimate of HR for heart failure patients. Fig. S4 Funnel plot (A) and leave-one-out (B) analysis of contribution of each miRNA in overall effect estimate of aHR for HFrEF patients. Fig. S5 Forest plot of pooled HR (A), funnel plot (B), and leave-one-out (C) analysis of contribution of each miRNA in overall effect estimate of HR for HFrEF patients. Fig. S6 Funnel plot (A) and leave-one-out (B) analysis of contribution of each miRNA in overall effect estimate of aHR/HR for HFpEF patients. Fig. S7 MiRNAs potential in risk stratification of heart failure patients in different outcomes. Fig. S8 Forest plot for HR (95% CI) (A) and AUC (95% CI) (B) for individual miRNAs in HFrEF and HFpEF, as well as for HF incidence. Table S1 Overview of risk of bias (low&#x02009;=&#x02009;&#x1f603;, moderate&#x02009;=&#x000a0;&#x1f611;&#x02009;, high&#x02009;=&#x000a0;&#x1f621;) within the QUIPS domains per included study. Table S2 Summary of the 22 included prognostic studies in qualitative analysis. Table S3 Characteristics of 22 studies included in quantitative analysis.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12916_2025_4238_MOESM2_ESM.docx"><caption><p>Additional file 2: PRISMA 2020 checklist.</p></caption></media></supplementary-material></p></sec></body><back><glossary id="AGS1"><title>Abbreviations</title><def-list><def-item><term>HF</term><def><p id="Par14">Heart failure</p></def></def-item><def-item><term>EF</term><def><p id="Par15">Ejection fraction</p></def></def-item><def-item><term>HFpEF</term><def><p id="Par16">Heart failure with preserved ejection fraction</p></def></def-item><def-item><term>HFrEF</term><def><p id="Par17">Heart failure with reduced ejection fraction</p></def></def-item><def-item><term>miRNA</term><def><p id="Par18">MicroRNA</p></def></def-item><def-item><term>KM</term><def><p id="Par19">Kaplan-Meier</p></def></def-item><def-item><term>IPD</term><def><p id="Par20">Individual patient data</p></def></def-item><def-item><term>HR</term><def><p id="Par21">Hazard ratio</p></def></def-item><def-item><term>aHR</term><def><p id="Par22">Adjusted hazard ratio</p></def></def-item><def-item><term>NT-proBNP</term><def><p id="Par23">N-terminal pro-B-type natriuretic peptide</p></def></def-item><def-item><term>BNP</term><def><p id="Par24">B-type natriuretic peptide</p></def></def-item><def-item><term>cTns</term><def><p id="Par25">Cardiac troponins</p></def></def-item><def-item><term>PRISMA</term><def><p id="Par26">Preferred Reporting Items for Systematic Reviews and Meta-Analyses</p></def></def-item><def-item><term>QUIPS</term><def><p id="Par27">Quality In Prognosis Studies</p></def></def-item><def-item><term>CI</term><def><p id="Par28">Confidence interval</p></def></def-item><def-item><term>AUC</term><def><p id="Par29">Area under the curve</p></def></def-item><def-item><term>AIC</term><def><p id="Par30">Akaike information criterion</p></def></def-item><def-item><term>LRT</term><def><p id="Par31">Likelihood ratio test</p></def></def-item><def-item><term>RMSE</term><def><p id="Par32">Root mean square error</p></def></def-item><def-item><term>CV</term><def><p id="Par33">Cardiovascular</p></def></def-item><def-item><term>CVD</term><def><p id="Par34">Cardiovascular disease</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>A list of authors and their affiliations appears at the end of the paper.</p></fn></fn-group><ack><title>Acknowledgements
</title><p>We gratefully acknowledge all the study&#x02019;s participants and patients, as well as the investigators participating in the studies.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>R.P., V.B., and M.H. contributed to the data extraction. R.P., V.B., M.H., Y.M., and G.J.J.S. performed the analysis and visualization. G.J.J.S. led the investigation. R.P., and Y.M. contributed to the statistical analysis. R.P., V.B., Y.D., M.F., and G.J.J.S. drafted the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by University of Oslo (incl Oslo University Hospital) This work is supported by the Norwegian Association for Public Health (grant No. 19560 to G.J.J.S.; grant No. 16040 to M.F.) and by the Research Council of Norway (grant No. 303150 to M.F.). Y.D. has received funding from the EU Horizon 2020 project COVIRNA (grant agreement #101016072), the COST Association (COST Actions CA17129 and CA21153), the National Research Fund (grants #C14/BM/8225223, C17/BM/11613033, and COVID-19/2020&#x02013;1/14719577/miRCOVID), the Ministry of Higher Education and Research, and the Heart Foundation-Daniel Wagner of Luxembourg. This article is based upon work from COST Action AtheroNET, CA21153, supported by COST (European Cooperation in Science and Technology).</p></notes><notes notes-type="data-availability"><title>Data availability
</title><p>&#x000a0;The data supporting the findings of this study will be available from the corresponding author upon reasonable request and with a signed data access agreement.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par70">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par71">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests
</title><p id="Par72">Y.D. holds patents on RNA biomarkers of cardiovascular disease and is a member of the scientific advisory board of the molecular diagnostics company Firalis SA. No other disclosures were reported.</p></notes></notes><ref-list id="Bib1"><title>References
</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>C</given-names></name><name><surname>Murdoch</surname><given-names>DR</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name></person-group><article-title>Economics of chronic heart failure</article-title><source>Eur J Heart Fail</source><year>2001</year><volume>3</volume><issue>3</issue><fpage>283</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/S1388-9842(01)00123-4</pub-id><?supplied-pmid 11377998?><pub-id pub-id-type="pmid">11377998</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail. 2001;3(3):283&#x02013;91.<pub-id pub-id-type="pmid">11377998</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Mosterd</surname><given-names>A</given-names></name><name><surname>Hoes</surname><given-names>AW</given-names></name></person-group><article-title>Clinical epidemiology of heart failure</article-title><source>Heart</source><year>2007</year><volume>93</volume><issue>9</issue><fpage>1137</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1136/hrt.2003.025270</pub-id><?supplied-pmid 17699180?><pub-id pub-id-type="pmid">17699180</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137&#x02013;46.<pub-id pub-id-type="pmid">17699180</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Groenewegen</surname><given-names>A</given-names></name><name><surname>Rutten</surname><given-names>FH</given-names></name><name><surname>Mosterd</surname><given-names>A</given-names></name><name><surname>Hoes</surname><given-names>AW</given-names></name></person-group><article-title>Epidemiology of heart failure</article-title><source>Eur J Heart Fail</source><year>2020</year><volume>22</volume><issue>8</issue><fpage>1342</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1002/ejhf.1858</pub-id><?supplied-pmid 32483830?><pub-id pub-id-type="pmid">32483830</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342&#x02013;56.<pub-id pub-id-type="pmid">32483830</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>McDonagh</surname><given-names>TA</given-names></name><name><surname>Metra</surname><given-names>M</given-names></name><name><surname>Adamo</surname><given-names>M</given-names></name><name><surname>Gardner</surname><given-names>RS</given-names></name><name><surname>Baumbach</surname><given-names>A</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>M</given-names></name><etal/></person-group><article-title>2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC</article-title><source>Rev Esp Cardiol (Engl Ed)</source><year>2022</year><volume>75</volume><issue>6</issue><fpage>523</fpage><?supplied-pmid 35636830?><pub-id pub-id-type="pmid">35636830</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B&#x000f6;hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Rev Esp Cardiol (Engl Ed). 2022;75(6):523.<pub-id pub-id-type="pmid">35636830</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Shrivastava</surname><given-names>A</given-names></name><name><surname>Haase</surname><given-names>T</given-names></name><name><surname>Zeller</surname><given-names>T</given-names></name><name><surname>Schulte</surname><given-names>C</given-names></name></person-group><article-title>Biomarkers for heart failure prognosis: proteins, genetic scores and non-coding RNAs</article-title><source>Front Cardiovasc Med</source><year>2020</year><volume>7</volume><fpage>601364</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2020.601364</pub-id><?supplied-pmid 33330662?><pub-id pub-id-type="pmid">33330662</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Shrivastava A, Haase T, Zeller T, Schulte C. Biomarkers for heart failure prognosis: proteins, genetic scores and non-coding RNAs. Front Cardiovasc Med. 2020;7: 601364.<pub-id pub-id-type="pmid">33330662</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>McDonagh</surname><given-names>TA</given-names></name><name><surname>Metra</surname><given-names>M</given-names></name><name><surname>Adamo</surname><given-names>M</given-names></name><name><surname>Gardner</surname><given-names>RS</given-names></name><name><surname>Baumbach</surname><given-names>A</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>M</given-names></name><etal/></person-group><article-title>2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC</article-title><source>EUR HEART J</source><year>2023</year><volume>44</volume><issue>37</issue><fpage>3627</fpage><lpage>3639</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad195</pub-id><?supplied-pmid 37622666?><pub-id pub-id-type="pmid">37622666</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B&#x000f6;hm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. EUR HEART J. 2023;44(37):3627&#x02013;39.<pub-id pub-id-type="pmid">37622666</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Bayes-Genis</surname><given-names>A</given-names></name><name><surname>Lanfear</surname><given-names>DE</given-names></name><name><surname>de Ronde</surname><given-names>MWJ</given-names></name><name><surname>Lupon</surname><given-names>J</given-names></name><name><surname>Leenders</surname><given-names>JJ</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients</article-title><source>Eur J Heart Fail</source><year>2018</year><volume>20</volume><issue>1</issue><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1002/ejhf.984</pub-id><?supplied-pmid 28949058?><pub-id pub-id-type="pmid">28949058</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bayes-Genis A, Lanfear DE, de Ronde MWJ, Lupon J, Leenders JJ, Liu Z, et al. Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients. Eur J Heart Fail. 2018;20(1):67&#x02013;75.<pub-id pub-id-type="pmid">28949058</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Gilad</surname><given-names>S</given-names></name><name><surname>Meiri</surname><given-names>E</given-names></name><name><surname>Yogev</surname><given-names>Y</given-names></name><name><surname>Benjamin</surname><given-names>S</given-names></name><name><surname>Lebanony</surname><given-names>D</given-names></name><name><surname>Yerushalmi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Serum microRNAs are promising novel biomarkers</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><issue>9</issue><fpage>e3148</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0003148</pub-id><?supplied-pmid 18773077?><pub-id pub-id-type="pmid">18773077</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE. 2008;3(9): e3148.<pub-id pub-id-type="pmid">18773077</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>CPC</given-names></name><name><surname>Schroen</surname><given-names>B</given-names></name><name><surname>Kuster</surname><given-names>GM</given-names></name><name><surname>Robinson</surname><given-names>EL</given-names></name><name><surname>Ford</surname><given-names>K</given-names></name><name><surname>Squire</surname><given-names>IB</given-names></name><etal/></person-group><article-title>Regulatory RNAs in heart failure</article-title><source>Circulation</source><year>2020</year><volume>141</volume><issue>4</issue><fpage>313</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.042474</pub-id><?supplied-pmid 31986093?><pub-id pub-id-type="pmid">31986093</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Gomes CPC, Schroen B, Kuster GM, Robinson EL, Ford K, Squire IB, et al. Regulatory RNAs in heart failure. Circulation. 2020;141(4):313&#x02013;28.<pub-id pub-id-type="pmid">31986093</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Gebert</surname><given-names>LFR</given-names></name><name><surname>MacRae</surname><given-names>IJ</given-names></name></person-group><article-title>Regulation of microRNA function in animals</article-title><source>Nat Rev Mol Cell Biol</source><year>2019</year><volume>20</volume><issue>1</issue><fpage>21</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1038/s41580-018-0045-7</pub-id><?supplied-pmid 30108335?><pub-id pub-id-type="pmid">30108335</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20(1):21&#x02013;37.<pub-id pub-id-type="pmid">30108335</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Devaux</surname><given-names>Y</given-names></name><name><surname>Dankiewicz</surname><given-names>J</given-names></name><name><surname>Salgado-Somoza</surname><given-names>A</given-names></name><name><surname>Stammet</surname><given-names>P</given-names></name><name><surname>Collignon</surname><given-names>O</given-names></name><name><surname>Gilje</surname><given-names>P</given-names></name><etal/></person-group><article-title>Association of circulating microRNA-124-3p levels with outcomes after out-of-hospital cardiac arrest: a substudy of a randomized clinical trial</article-title><source>JAMA Cardiol</source><year>2016</year><volume>1</volume><issue>3</issue><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2016.0480</pub-id><?supplied-pmid 27438111?><pub-id pub-id-type="pmid">27438111</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Devaux Y, Dankiewicz J, Salgado-Somoza A, Stammet P, Collignon O, Gilje P, et al. Association of circulating microRNA-124-3p levels with outcomes after out-of-hospital cardiac arrest: a substudy of a randomized clinical trial. JAMA Cardiol. 2016;1(3):305&#x02013;13.<pub-id pub-id-type="pmid">27438111</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>RV</given-names></name><name><surname>Rong</surname><given-names>J</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><name><surname>Yeri</surname><given-names>A</given-names></name><name><surname>Ziegler</surname><given-names>O</given-names></name><name><surname>Tanriverdi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Associations of circulating extracellular RNAs with myocardial remodeling and heart failure</article-title><source>JAMA Cardiol</source><year>2018</year><volume>3</volume><issue>9</issue><fpage>871</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2018.2371</pub-id><?supplied-pmid 30090932?><pub-id pub-id-type="pmid">30090932</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Shah RV, Rong J, Larson MG, Yeri A, Ziegler O, Tanriverdi K, et al. Associations of circulating extracellular RNAs with myocardial remodeling and heart failure. JAMA Cardiol. 2018;3(9):871&#x02013;6.<pub-id pub-id-type="pmid">30090932</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname><given-names>S</given-names></name><name><surname>Batkai</surname><given-names>S</given-names></name><name><surname>Beermann</surname><given-names>J</given-names></name><name><surname>Bar</surname><given-names>C</given-names></name><name><surname>Pfanne</surname><given-names>A</given-names></name><name><surname>Thum</surname><given-names>S</given-names></name><etal/></person-group><article-title>Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure</article-title><source>Eur J Heart Fail</source><year>2018</year><volume>20</volume><issue>1</issue><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1002/ejhf.961</pub-id><?supplied-pmid 29027324?><pub-id pub-id-type="pmid">29027324</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Masson S, Batkai S, Beermann J, Bar C, Pfanne A, Thum S, et al. Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. Eur J Heart Fail. 2018;20(1):78&#x02013;85.<pub-id pub-id-type="pmid">29027324</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>McInnes</surname><given-names>MDF</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Thombs</surname><given-names>BD</given-names></name><name><surname>McGrath</surname><given-names>TA</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Clifford</surname><given-names>T</given-names></name><etal/></person-group><article-title>Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement</article-title><source>JAMA</source><year>2018</year><volume>319</volume><issue>4</issue><fpage>388</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1001/jama.2017.19163</pub-id><?supplied-pmid 29362800?><pub-id pub-id-type="pmid">29362800</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388&#x02013;96.<pub-id pub-id-type="pmid">29362800</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Parvan</surname><given-names>R</given-names></name><name><surname>Hosseinpour</surname><given-names>M</given-names></name><name><surname>Moradi</surname><given-names>Y</given-names></name><name><surname>Devaux</surname><given-names>Y</given-names></name><name><surname>Cataliotti</surname><given-names>A</given-names></name><name><surname>da Silva</surname><given-names>GJJ</given-names></name></person-group><article-title>Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: a systematic review and meta-analysis</article-title><source>Eur J Heart Fail</source><year>2022</year><volume>24</volume><issue>12</issue><fpage>2212</fpage><lpage>2225</lpage><pub-id pub-id-type="doi">10.1002/ejhf.2700</pub-id><?supplied-pmid 36161443?><pub-id pub-id-type="pmid">36161443</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Parvan R, Hosseinpour M, Moradi Y, Devaux Y, Cataliotti A, da Silva GJJ. Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail. 2022;24(12):2212&#x02013;25.<pub-id pub-id-type="pmid">36161443</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>RD</given-names></name><name><surname>Moons</surname><given-names>KGM</given-names></name><name><surname>Snell</surname><given-names>KIE</given-names></name><name><surname>Ensor</surname><given-names>J</given-names></name><name><surname>Hooft</surname><given-names>L</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><etal/></person-group><article-title>A guide to systematic review and meta-analysis of prognostic factor studies</article-title><source>BMJ</source><year>2019</year><volume>364</volume><fpage>k4597</fpage><pub-id pub-id-type="doi">10.1136/bmj.k4597</pub-id><?supplied-pmid 30700442?><pub-id pub-id-type="pmid">30700442</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Riley RD, Moons KGM, Snell KIE, Ensor J, Hooft L, Altman DG, et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ. 2019;364: k4597.<pub-id pub-id-type="pmid">30700442</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Grooten</surname><given-names>WJA</given-names></name><name><surname>Tseli</surname><given-names>E</given-names></name><name><surname>Ang</surname><given-names>BO</given-names></name><name><surname>Boersma</surname><given-names>K</given-names></name><name><surname>Stalnacke</surname><given-names>BM</given-names></name><name><surname>Gerdle</surname><given-names>B</given-names></name><name><surname>Enthoven</surname><given-names>P</given-names></name></person-group><article-title>Elaborating on the assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS-aspects of interrater agreement</article-title><source>Diagn Progn Res</source><year>2019</year><volume>3</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1186/s41512-019-0050-0</pub-id><?supplied-pmid 31093575?><pub-id pub-id-type="pmid">31093575</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Grooten WJA, Tseli E, Ang BO, Boersma K, Stalnacke BM, Gerdle B, Enthoven P. Elaborating on the assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS-aspects of interrater agreement. Diagn Progn Res. 2019;3:5.<pub-id pub-id-type="pmid">31093575</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>DerSimonian</surname><given-names>R</given-names></name><name><surname>Laird</surname><given-names>N</given-names></name></person-group><article-title>Meta-analysis in clinical trials</article-title><source>Control Clin Trials</source><year>1986</year><volume>7</volume><issue>3</issue><fpage>177</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/0197-2456(86)90046-2</pub-id><?supplied-pmid 3802833?><pub-id pub-id-type="pmid">3802833</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177&#x02013;88.<pub-id pub-id-type="pmid">3802833</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name></person-group><article-title>IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves</article-title><source>BMC Med Res Methodol</source><year>2021</year><volume>21</volume><issue>1</issue><fpage>111</fpage><pub-id pub-id-type="doi">10.1186/s12874-021-01308-8</pub-id><?supplied-pmid 34074267?><pub-id pub-id-type="pmid">34074267</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21(1):111.<pub-id pub-id-type="pmid">34074267</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>G</given-names></name></person-group><article-title>Clinical value of circulating ZFAS1 and miR-590-3p in the diagnosis and prognosis of chronic heart failure</article-title><source>Cardiovasc Toxicol</source><year>2021</year><volume>21</volume><issue>11</issue><fpage>880</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1007/s12012-021-09678-7</pub-id><?supplied-pmid 34319554?><pub-id pub-id-type="pmid">34319554</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Chang G, Zhang W, Zhang M, Ding G. Clinical value of circulating ZFAS1 and miR-590-3p in the diagnosis and prognosis of chronic heart failure. Cardiovasc Toxicol. 2021;21(11):880&#x02013;8.<pub-id pub-id-type="pmid">34319554</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>WT</given-names></name><name><surname>Wu</surname><given-names>CC</given-names></name><name><surname>Lin</surname><given-names>YW</given-names></name><name><surname>Shih</surname><given-names>JY</given-names></name><name><surname>Chen</surname><given-names>ZC</given-names></name><name><surname>Wu</surname><given-names>SN</given-names></name><etal/></person-group><article-title>Dynamic changes in miR-21 regulate right ventricular dysfunction in congenital heart disease-related pulmonary arterial hypertension</article-title><source>Cells</source><year>2022</year><volume>11</volume><issue>3</issue><fpage>564</fpage><pub-id pub-id-type="doi">10.3390/cells11030564</pub-id><?supplied-pmid 35159373?><pub-id pub-id-type="pmid">35159373</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Chang WT, Wu CC, Lin YW, Shih JY, Chen ZC, Wu SN, et al. Dynamic changes in miR-21 regulate right ventricular dysfunction in congenital heart disease-related pulmonary arterial hypertension. Cells. 2022;11(3):564.<pub-id pub-id-type="pmid">35159373</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Crocco</surname><given-names>P</given-names></name><name><surname>Montesanto</surname><given-names>A</given-names></name><name><surname>La Grotta</surname><given-names>R</given-names></name><name><surname>Paparazzo</surname><given-names>E</given-names></name><name><surname>Soraci</surname><given-names>L</given-names></name><name><surname>Dato</surname><given-names>S</given-names></name><etal/></person-group><article-title>The potential contribution of myomiRs miR-133a-3p, -133b, and -206 dysregulation in cardiovascular disease risk</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><issue>23</issue><fpage>12772</fpage><pub-id pub-id-type="doi">10.3390/ijms252312772</pub-id><?supplied-pmid 39684483?><pub-id pub-id-type="pmid">39684483</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Crocco P, Montesanto A, La Grotta R, Paparazzo E, Soraci L, Dato S, et al. The potential contribution of myomiRs miR-133a-3p, -133b, and -206 dysregulation in cardiovascular disease risk. Int J Mol Sci. 2024;25(23):12772.<pub-id pub-id-type="pmid">39684483</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Dantas-Komatsu</surname><given-names>RCS</given-names></name><name><surname>Cruz</surname><given-names>MS</given-names></name><name><surname>Freire</surname><given-names>PP</given-names></name><name><surname>Diniz</surname><given-names>RVZ</given-names></name><name><surname>Bortolin</surname><given-names>RH</given-names></name><name><surname>Cabral-Marques</surname><given-names>O</given-names></name><etal/></person-group><article-title>The let-7b-5p, miR-326, and miR-125a-3p are associated with left ventricular systolic dysfunction in post-myocardial infarction</article-title><source>Front Cardiovasc Med</source><year>2023</year><volume>10</volume><fpage>1151855</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2023.1151855</pub-id><?supplied-pmid 37252118?><pub-id pub-id-type="pmid">37252118</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Dantas-Komatsu RCS, Cruz MS, Freire PP, Diniz RVZ, Bortolin RH, Cabral-Marques O, et al. The let-7b-5p, miR-326, and miR-125a-3p are associated with left ventricular systolic dysfunction in post-myocardial infarction. Front Cardiovasc Med. 2023;10:1151855.<pub-id pub-id-type="pmid">37252118</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Gan</surname><given-names>S</given-names></name></person-group><article-title>miR-182-5p combined with brain-derived neurotrophic factor assists the diagnosis of chronic heart failure and predicts a poor prognosis</article-title><source>J Cardiothorac Surg</source><year>2022</year><volume>17</volume><issue>1</issue><fpage>88</fpage><pub-id pub-id-type="doi">10.1186/s13019-022-01802-0</pub-id><?supplied-pmid 35501813?><pub-id pub-id-type="pmid">35501813</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Fang F, Zhang X, Li B, Gan S. miR-182-5p combined with brain-derived neurotrophic factor assists the diagnosis of chronic heart failure and predicts a poor prognosis. J Cardiothorac Surg. 2022;17(1):88.<pub-id pub-id-type="pmid">35501813</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Gidl&#x000f6;f</surname><given-names>O</given-names></name><name><surname>Smith</surname><given-names>JG</given-names></name><name><surname>Miyazu</surname><given-names>K</given-names></name><name><surname>Gilje</surname><given-names>P</given-names></name><name><surname>Spencer</surname><given-names>A</given-names></name><name><surname>Blomquist</surname><given-names>S</given-names></name><name><surname>Erlinge</surname><given-names>D</given-names></name></person-group><article-title>Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction</article-title><source>BMC CARDIOVASCULAR DISORDERS</source><year>2013</year><volume>13</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/1471-2261-13-12</pub-id><?supplied-pmid 23448306?><pub-id pub-id-type="pmid">23448306</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Gidl&#x000f6;f O, Smith JG, Miyazu K, Gilje P, Spencer A, Blomquist S, Erlinge D. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovascular Disorders. 2013;13:12.<pub-id pub-id-type="pmid">23448306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>S</given-names></name><etal/></person-group><article-title>Circulating miR-208b and miR-34a are associated with left ventricular remodeling after acute myocardial infarction</article-title><source>Int J Mol Sci</source><year>2014</year><volume>15</volume><issue>4</issue><fpage>5774</fpage><lpage>5788</lpage><pub-id pub-id-type="doi">10.3390/ijms15045774</pub-id><?supplied-pmid 24714087?><pub-id pub-id-type="pmid">24714087</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Lv P, Zhou M, He J, Meng W, Ma X, Dong S, et al. Circulating miR-208b and miR-34a are associated with left ventricular remodeling after acute myocardial infarction. Int J Mol Sci. 2014;15(4):5774&#x02013;88.<pub-id pub-id-type="pmid">24714087</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Marketou</surname><given-names>M</given-names></name><name><surname>Kontaraki</surname><given-names>J</given-names></name><name><surname>Zacharis</surname><given-names>E</given-names></name><name><surname>Maragkoudakis</surname><given-names>S</given-names></name><name><surname>Fragkiadakis</surname><given-names>K</given-names></name><name><surname>Kampanieris</surname><given-names>E</given-names></name><etal/></person-group><article-title>Peripheral blood microRNA-21 as a predictive biomarker for heart failure with preserved ejection fraction in old hypertensives</article-title><source>Am J Hypertens</source><year>2024</year><volume>37</volume><issue>4</issue><fpage>298</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1093/ajh/hpad109</pub-id><?supplied-pmid 37976292?><pub-id pub-id-type="pmid">37976292</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Marketou M, Kontaraki J, Zacharis E, Maragkoudakis S, Fragkiadakis K, Kampanieris E, et al. Peripheral blood microRNA-21 as a predictive biomarker for heart failure with preserved ejection fraction in old hypertensives. Am J Hypertens. 2024;37(4):298&#x02013;305.<pub-id pub-id-type="pmid">37976292</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Qiang</surname><given-names>L</given-names></name><name><surname>Hong</surname><given-names>L</given-names></name><name><surname>Ningfu</surname><given-names>W</given-names></name><name><surname>Huaihong</surname><given-names>C</given-names></name><name><surname>Jing</surname><given-names>W</given-names></name></person-group><article-title>Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients</article-title><source>Int J Cardiol</source><year>2013</year><volume>168</volume><issue>3</issue><fpage>2082</fpage><lpage>2088</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2013.01.160</pub-id><?supplied-pmid 23465244?><pub-id pub-id-type="pmid">23465244</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Qiang L, Hong L, Ningfu W, Huaihong C, Jing W. Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients. Int J Cardiol. 2013;168(3):2082&#x02013;8.<pub-id pub-id-type="pmid">23465244</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Rincon</surname><given-names>LM</given-names></name><name><surname>Rodriguez-Serrano</surname><given-names>M</given-names></name><name><surname>Conde</surname><given-names>E</given-names></name><name><surname>Lanza</surname><given-names>VF</given-names></name><name><surname>Sanmartin</surname><given-names>M</given-names></name><name><surname>Gonzalez-Portilla</surname><given-names>P</given-names></name><etal/></person-group><article-title>Serum microRNAs are key predictors of long-term heart failure and cardiovascular death after myocardial infarction</article-title><source>ESC Heart Fail</source><year>2022</year><volume>9</volume><issue>5</issue><fpage>3367</fpage><lpage>3379</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13919</pub-id><?supplied-pmid 35837763?><pub-id pub-id-type="pmid">35837763</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Rincon LM, Rodriguez-Serrano M, Conde E, Lanza VF, Sanmartin M, Gonzalez-Portilla P, et al. Serum microRNAs are key predictors of long-term heart failure and cardiovascular death after myocardial infarction. ESC Heart Fail. 2022;9(5):3367&#x02013;79.<pub-id pub-id-type="pmid">35837763</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>Circulating mir-199&#x02013;3p screens the onset of type 2 diabetes mellitus and the complication of coronary heart disease and predicts the occurrence of major adverse cardiovascular events</article-title><source>BMC Cardiovascular Disorders</source><year>2023</year><volume>23</volume><issue>1</issue><fpage>563</fpage><pub-id pub-id-type="doi">10.1186/s12872-023-03601-4</pub-id><?supplied-pmid 37974073?><pub-id pub-id-type="pmid">37974073</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ruan R, Liu Y, Zhang X. Circulating mir-199&#x02013;3p screens the onset of type 2 diabetes mellitus and the complication of coronary heart disease and predicts the occurrence of major adverse cardiovascular events. BMC Cardiovascular Disorders. 2023;23(1):563.<pub-id pub-id-type="pmid">37974073</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Scrutinio</surname><given-names>D</given-names></name><name><surname>Conserva</surname><given-names>F</given-names></name><name><surname>Passantino</surname><given-names>A</given-names></name><name><surname>Iacoviello</surname><given-names>M</given-names></name><name><surname>Lagioia</surname><given-names>R</given-names></name><name><surname>Gesualdo</surname><given-names>L</given-names></name></person-group><article-title>Circulating microRNA-150-5p as a novel biomarker for advanced heart failure: a genome-wide prospective study</article-title><source>J Heart Lung Transplant</source><year>2017</year><volume>36</volume><issue>6</issue><fpage>616</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2017.02.008</pub-id><?supplied-pmid 28259597?><pub-id pub-id-type="pmid">28259597</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Scrutinio D, Conserva F, Passantino A, Iacoviello M, Lagioia R, Gesualdo L. Circulating microRNA-150-5p as a novel biomarker for advanced heart failure: a genome-wide prospective study. J Heart Lung Transplant. 2017;36(6):616&#x02013;24.<pub-id pub-id-type="pmid">28259597</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Spahillari</surname><given-names>A</given-names></name><name><surname>Jackson</surname><given-names>L</given-names></name><name><surname>Varrias</surname><given-names>D</given-names></name><name><surname>Michelhaugh</surname><given-names>SA</given-names></name><name><surname>Januzzi</surname><given-names>JL</given-names></name><name><surname>Shahideh</surname><given-names>B</given-names></name><etal/></person-group><article-title>MicroRNAs are associated with cardiac biomarkers, cardiac structure and function and incident outcomes in heart failure</article-title><source>ESC Heart Fail</source><year>2024</year><volume>11</volume><issue>3</issue><fpage>1400</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1002/ehf2.14649</pub-id><?supplied-pmid 38321808?><pub-id pub-id-type="pmid">38321808</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Spahillari A, Jackson L, Varrias D, Michelhaugh SA, Januzzi JL, Shahideh B, et al. MicroRNAs are associated with cardiac biomarkers, cardiac structure and function and incident outcomes in heart failure. ESC Heart Fail. 2024;11(3):1400&#x02013;10.<pub-id pub-id-type="pmid">38321808</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Spinka</surname><given-names>G</given-names></name><name><surname>Bartko</surname><given-names>PE</given-names></name><name><surname>Pavo</surname><given-names>N</given-names></name><name><surname>Freitag</surname><given-names>C</given-names></name><name><surname>Zlabinger</surname><given-names>K</given-names></name><name><surname>Prausmuller</surname><given-names>S</given-names></name><etal/></person-group><article-title>Secondary mitral regurgitation-Insights from microRNA assessment</article-title><source>Eur J Clin Invest</source><year>2021</year><volume>51</volume><issue>2</issue><fpage>e13381</fpage><pub-id pub-id-type="doi">10.1111/eci.13381</pub-id><?supplied-pmid 32780418?><pub-id pub-id-type="pmid">32780418</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Spinka G, Bartko PE, Pavo N, Freitag C, Zlabinger K, Prausmuller S, et al. Secondary mitral regurgitation-Insights from microRNA assessment. Eur J Clin Invest. 2021;51(2): e13381.<pub-id pub-id-type="pmid">32780418</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Stojkovic</surname><given-names>S</given-names></name><name><surname>Koller</surname><given-names>L</given-names></name><name><surname>Sulzgruber</surname><given-names>P</given-names></name><name><surname>Hulsmann</surname><given-names>M</given-names></name><name><surname>Huber</surname><given-names>K</given-names></name><name><surname>Mayr</surname><given-names>M</given-names></name><etal/></person-group><article-title>Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure</article-title><source>Int J Cardiol</source><year>2020</year><volume>303</volume><fpage>80</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2019.11.090</pub-id><?supplied-pmid 31757654?><pub-id pub-id-type="pmid">31757654</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Stojkovic S, Koller L, Sulzgruber P, Hulsmann M, Huber K, Mayr M, et al. Liver-specific microRNA-122 as prognostic biomarker in patients with chronic systolic heart failure. Int J Cardiol. 2020;303:80&#x02013;5.<pub-id pub-id-type="pmid">31757654</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Vogel</surname><given-names>B</given-names></name><name><surname>Keller</surname><given-names>A</given-names></name><name><surname>Frese</surname><given-names>KS</given-names></name><name><surname>Leidinger</surname><given-names>P</given-names></name><name><surname>Sedaghat-Hamedani</surname><given-names>F</given-names></name><name><surname>Kayvanpour</surname><given-names>E</given-names></name><etal/></person-group><article-title>Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><issue>36</issue><fpage>2812</fpage><lpage>2822</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/eht256</pub-id><?supplied-pmid 23864135?><pub-id pub-id-type="pmid">23864135</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Vogel B, Keller A, Frese KS, Leidinger P, Sedaghat-Hamedani F, Kayvanpour E, et al. Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure. Eur Heart J. 2013;34(36):2812&#x02013;22.<pub-id pub-id-type="pmid">23864135</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>R</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name></person-group><article-title>Subtypes identification on heart failure with preserved ejection fraction via network enhancement fusion using multi-omics data</article-title><source>Comput Struct Biotechnol J</source><year>2021</year><volume>19</volume><fpage>1567</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2021.03.010</pub-id><?supplied-pmid 33868594?><pub-id pub-id-type="pmid">33868594</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Wu Y, Wang H, Li Z, Cheng J, Fang R, Cao H, Cui Y. Subtypes identification on heart failure with preserved ejection fraction via network enhancement fusion using multi-omics data. Comput Struct Biotechnol J. 2021;19:1567&#x02013;78.<pub-id pub-id-type="pmid">33868594</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Hang</surname><given-names>JZ</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name></person-group><article-title>Clinical significance of miR-27a expression in serum exosomes in patients with heart failure</article-title><source>Cell Mol Biol (Noisy-le-grand).</source><year>2022</year><volume>67</volume><issue>5</issue><fpage>324</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.14715/cmb/2021.67.5.44</pub-id><?supplied-pmid 35818236?><pub-id pub-id-type="pmid">35818236</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Xie Y, Hang JZ, Zhang N, Liu G. Clinical significance of miR-27a expression in serum exosomes in patients with heart failure. Cell Mol Biol (Noisy-le-grand). 2022;67(5):324&#x02013;31.<pub-id pub-id-type="pmid">35818236</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Lun</surname><given-names>X</given-names></name></person-group><article-title>Clinical significance of the long non-coding RNA NEAT1/miR-129-5p axis in the diagnosis and prognosis for patients with chronic heart failure</article-title><source>Exp Ther Med</source><year>2021</year><volume>21</volume><issue>5</issue><fpage>512</fpage><pub-id pub-id-type="doi">10.3892/etm.2021.9943</pub-id><?supplied-pmid 33791021?><pub-id pub-id-type="pmid">33791021</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Zhang H, Zhang N, Jiang W, Lun X. Clinical significance of the long non-coding RNA NEAT1/miR-129-5p axis in the diagnosis and prognosis for patients with chronic heart failure. Exp Ther Med. 2021;21(5):512.<pub-id pub-id-type="pmid">33791021</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Ji</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>Sui</surname><given-names>Y</given-names></name></person-group><article-title>Differentially expressed TUG1 and miR-145-5p indicate different severity of chronic heart failure and predict 2-year survival prognosis</article-title><source>Exp Ther Med</source><year>2021</year><volume>22</volume><issue>6</issue><fpage>1362</fpage><pub-id pub-id-type="doi">10.3892/etm.2021.10796</pub-id><?supplied-pmid 34659508?><pub-id pub-id-type="pmid">34659508</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Zhu Q, Li S, Ji K, Zhou H, Luo C, Sui Y. Differentially expressed TUG1 and miR-145-5p indicate different severity of chronic heart failure and predict 2-year survival prognosis. Exp Ther Med. 2021;22(6):1362.<pub-id pub-id-type="pmid">34659508</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Shahim</surname><given-names>B</given-names></name><name><surname>Kapelios</surname><given-names>CJ</given-names></name><name><surname>Savarese</surname><given-names>G</given-names></name><name><surname>Lund</surname><given-names>LH</given-names></name></person-group><article-title>Global public health burden of heart failure: an updated review</article-title><source>Card Fail Rev</source><year>2023</year><volume>9</volume><fpage>e11</fpage><pub-id pub-id-type="doi">10.15420/cfr.2023.05</pub-id><?supplied-pmid 37547123?><pub-id pub-id-type="pmid">37547123</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: an updated review. Card Fail Rev. 2023;9: e11.<pub-id pub-id-type="pmid">37547123</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Buchan</surname><given-names>TA</given-names></name><name><surname>Ching</surname><given-names>C</given-names></name><name><surname>Foroutan</surname><given-names>F</given-names></name><name><surname>Malik</surname><given-names>A</given-names></name><name><surname>Daza</surname><given-names>JF</given-names></name><name><surname>Hing</surname><given-names>NNF</given-names></name><etal/></person-group><article-title>Prognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis</article-title><source>Heart Fail Rev</source><year>2022</year><volume>27</volume><issue>2</issue><fpage>645</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1007/s10741-021-10136-3</pub-id><?supplied-pmid 34227029?><pub-id pub-id-type="pmid">34227029</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Buchan TA, Ching C, Foroutan F, Malik A, Daza JF, Hing NNF, et al. Prognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis. Heart Fail Rev. 2022;27(2):645&#x02013;54.<pub-id pub-id-type="pmid">34227029</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhong</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name></person-group><article-title>Prognostic value of microRNAs in acute myocardial infarction: a systematic review and meta-analysis</article-title><source>Int J Cardiol</source><year>2015</year><volume>189</volume><fpage>79</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2015.04.055</pub-id><?supplied-pmid 25885877?><pub-id pub-id-type="pmid">25885877</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Cao W, Guo Q, Zhang T, Zhong D, Yu Q. Prognostic value of microRNAs in acute myocardial infarction: a systematic review and meta-analysis. Int J Cardiol. 2015;189:79&#x02013;84.<pub-id pub-id-type="pmid">25885877</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Rech</surname><given-names>M</given-names></name><name><surname>Barandiaran Aizpurua</surname><given-names>A</given-names></name><name><surname>van Empel</surname><given-names>V</given-names></name><name><surname>van Bilsen</surname><given-names>M</given-names></name><name><surname>Schroen</surname><given-names>B</given-names></name></person-group><article-title>Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle</article-title><source>Cardiovasc Res</source><year>2018</year><volume>114</volume><issue>6</issue><fpage>782</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvy049</pub-id><?supplied-pmid 29462282?><pub-id pub-id-type="pmid">29462282</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Rech M, Barandiaran Aizpurua A, van Empel V, van Bilsen M, Schroen B. Pathophysiological understanding of HFpEF: microRNAs as part of the puzzle. Cardiovasc Res. 2018;114(6):782&#x02013;93.<pub-id pub-id-type="pmid">29462282</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><article-title>Downregulation of lncRNA ZFAS1 protects H9c2 cardiomyocytes from ischemia/reperfusion-induced apoptosis via the miR-590-3p/NF-&#x003ba;B signaling pathway</article-title><source>Mol Med Rep</source><year>2020</year><volume>22</volume><issue>3</issue><fpage>2300</fpage><lpage>2306</lpage><pub-id pub-id-type="doi">10.3892/mmr.2020.11340</pub-id><?supplied-pmid 32705215?><pub-id pub-id-type="pmid">32705215</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Huang P, Yang D, Yu L, Shi Y. Downregulation of lncRNA ZFAS1 protects H9c2 cardiomyocytes from ischemia/reperfusion-induced apoptosis via the miR-590-3p/NF-&#x003ba;B signaling pathway. Mol Med Rep. 2020;22(3):2300&#x02013;6.<pub-id pub-id-type="pmid">32705215</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>FZ</given-names></name><name><surname>Vizi</surname><given-names>D</given-names></name><name><surname>Khammy</surname><given-names>O</given-names></name><name><surname>Mariani</surname><given-names>JA</given-names></name><name><surname>Kaye</surname><given-names>DM</given-names></name></person-group><article-title>The transcardiac gradient of cardio-microRNAs in the failing heart</article-title><source>Eur J Heart Fail</source><year>2016</year><volume>18</volume><issue>8</issue><fpage>1000</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1002/ejhf.517</pub-id><?supplied-pmid 27072074?><pub-id pub-id-type="pmid">27072074</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Marques FZ, Vizi D, Khammy O, Mariani JA, Kaye DM. The transcardiac gradient of cardio-microRNAs in the failing heart. Eur J Heart Fail. 2016;18(8):1000&#x02013;8.<pub-id pub-id-type="pmid">27072074</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Corsten</surname><given-names>MF</given-names></name><name><surname>Dennert</surname><given-names>R</given-names></name><name><surname>Jochems</surname><given-names>S</given-names></name><name><surname>Kuznetsova</surname><given-names>T</given-names></name><name><surname>Devaux</surname><given-names>Y</given-names></name><name><surname>Hofstra</surname><given-names>L</given-names></name><etal/></person-group><article-title>Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease</article-title><source>Circ Cardiovasc Genet</source><year>2010</year><volume>3</volume><issue>6</issue><fpage>499</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1161/CIRCGENETICS.110.957415</pub-id><?supplied-pmid 20921333?><pub-id pub-id-type="pmid">20921333</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010;3(6):499&#x02013;506.<pub-id pub-id-type="pmid">20921333</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Hosen</surname><given-names>MR</given-names></name><name><surname>Goody</surname><given-names>PR</given-names></name><name><surname>Zietzer</surname><given-names>A</given-names></name><name><surname>Xiang</surname><given-names>X</given-names></name><name><surname>Niepmann</surname><given-names>ST</given-names></name><name><surname>Sedaghat</surname><given-names>A</given-names></name><etal/></person-group><article-title>Circulating microRNA-122-5p is associated with a lack of improvement in left ventricular function after transcatheter aortic valve replacement and regulates viability of cardiomyocytes through extracellular vesicles</article-title><source>Circulation</source><year>2022</year><volume>146</volume><issue>24</issue><fpage>1836</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.122.060258</pub-id><?supplied-pmid 35862223?><pub-id pub-id-type="pmid">35862223</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Hosen MR, Goody PR, Zietzer A, Xiang X, Niepmann ST, Sedaghat A, et al. Circulating microRNA-122-5p is associated with a lack of improvement in left ventricular function after transcatheter aortic valve replacement and regulates viability of cardiomyocytes through extracellular vesicles. Circulation. 2022;146(24):1836&#x02013;54.<pub-id pub-id-type="pmid">35862223</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>KL</given-names></name><name><surname>Zhang</surname><given-names>HF</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>XL</given-names></name></person-group><article-title>Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy</article-title><source>Indian Heart J</source><year>2013</year><volume>65</volume><issue>1</issue><fpage>12</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.ihj.2012.12.022</pub-id><?supplied-pmid 23438607?><pub-id pub-id-type="pmid">23438607</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Fan KL, Zhang HF, Shen J, Zhang Q, Li XL. Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart J. 2013;65(1):12&#x02013;6.<pub-id pub-id-type="pmid">23438607</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Tijsen</surname><given-names>AJ</given-names></name><name><surname>Creemers</surname><given-names>EE</given-names></name><name><surname>Moerland</surname><given-names>PD</given-names></name><name><surname>de Windt</surname><given-names>LJ</given-names></name><name><surname>van der Wal</surname><given-names>AC</given-names></name><name><surname>Kok</surname><given-names>WE</given-names></name><name><surname>Pinto</surname><given-names>YM</given-names></name></person-group><article-title>MiR423-5p as a circulating biomarker for heart failure</article-title><source>Circ Res</source><year>2010</year><volume>106</volume><issue>6</issue><fpage>1035</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.218297</pub-id><?supplied-pmid 20185794?><pub-id pub-id-type="pmid">20185794</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106(6):1035&#x02013;9.<pub-id pub-id-type="pmid">20185794</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Taubel</surname><given-names>J</given-names></name><name><surname>Hauke</surname><given-names>W</given-names></name><name><surname>Rump</surname><given-names>S</given-names></name><name><surname>Viereck</surname><given-names>J</given-names></name><name><surname>Batkai</surname><given-names>S</given-names></name><name><surname>Poetzsch</surname><given-names>J</given-names></name><etal/></person-group><article-title>Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study</article-title><source>Eur Heart J</source><year>2021</year><volume>42</volume><issue>2</issue><fpage>178</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa898</pub-id><?supplied-pmid 33245749?><pub-id pub-id-type="pmid">33245749</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Taubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetzsch J, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021;42(2):178&#x02013;88.<pub-id pub-id-type="pmid">33245749</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name></person-group><article-title>Circulating microRNAs as novel potential biomarkers for left ventricular remodeling in postinfarction heart failure</article-title><source>Dis Markers</source><year>2019</year><volume>2019</volume><fpage>5093803</fpage><pub-id pub-id-type="doi">10.1155/2019/5093803</pub-id><?supplied-pmid 31885737?><pub-id pub-id-type="pmid">31885737</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Gao G, Chen W, Liu M, Yan X, Yang P. Circulating microRNAs as novel potential biomarkers for left ventricular remodeling in postinfarction heart failure. Dis Markers. 2019;2019:5093803.<pub-id pub-id-type="pmid">31885737</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>R</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Diagnostic value of miRNA expression and right ventricular echocardiographic functional parameters for chronic thromboembolic pulmonary hypertension with right ventricular dysfunction and injury</article-title><source>BMC Pulm Med</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>171</fpage><pub-id pub-id-type="doi">10.1186/s12890-022-01962-8</pub-id><?supplied-pmid 35488248?><pub-id pub-id-type="pmid">35488248</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Miao R, Gong J, Guo X, Guo D, Zhang X, Hu H, et al. Diagnostic value of miRNA expression and right ventricular echocardiographic functional parameters for chronic thromboembolic pulmonary hypertension with right ventricular dysfunction and injury. BMC Pulm Med. 2022;22(1):171.<pub-id pub-id-type="pmid">35488248</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Li X, Liu CY, Li YS, Xu J, Li DG, Li X, Han D. Deep RNA sequencing elucidates microRNA-regulated molecular pathways in ischemic cardiomyopathy and nonischemic cardiomyopathy. Genet Mol Res. 2016;15(2).</mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Rinc&#x000f3;n</surname><given-names>LM</given-names></name><name><surname>Rodr&#x000ed;guez-Serrano</surname><given-names>M</given-names></name><name><surname>Conde</surname><given-names>E</given-names></name><name><surname>Lanza</surname><given-names>VF</given-names></name><name><surname>Sanmart&#x000ed;n</surname><given-names>M</given-names></name><name><surname>Gonz&#x000e1;lez-Portilla</surname><given-names>P</given-names></name><etal/></person-group><article-title>Serum microRNAs are key predictors of long-term heart failure and cardiovascular death after myocardial infarction</article-title><source>ESC Heart Failure</source><year>2022</year><volume>9</volume><issue>5</issue><fpage>3367</fpage><lpage>3379</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13919</pub-id><?supplied-pmid 35837763?><pub-id pub-id-type="pmid">35837763</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Rinc&#x000f3;n LM, Rodr&#x000ed;guez-Serrano M, Conde E, Lanza VF, Sanmart&#x000ed;n M, Gonz&#x000e1;lez-Portilla P, et al. Serum microRNAs are key predictors of long-term heart failure and cardiovascular death after myocardial infarction. ESC Heart Failure. 2022;9(5):3367&#x02013;79.<pub-id pub-id-type="pmid">35837763</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Vaze</surname><given-names>A</given-names></name><name><surname>Tran</surname><given-names>K-V</given-names></name><name><surname>Tanriverdi</surname><given-names>K</given-names></name><name><surname>Sardana</surname><given-names>M</given-names></name><name><surname>Lessard</surname><given-names>D</given-names></name><name><surname>Donahue</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Relations between plasma microRNAs, echocardiographic markers of atrial remodeling, and atrial fibrillation: data from the Framingham Offspring study</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><issue>8</issue><fpage>e0236960</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0236960</pub-id><?supplied-pmid 32813736?><pub-id pub-id-type="pmid">32813736</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Vaze A, Tran K-V, Tanriverdi K, Sardana M, Lessard D, Donahue JK, et al. Relations between plasma microRNAs, echocardiographic markers of atrial remodeling, and atrial fibrillation: data from the Framingham Offspring study. PLoS ONE. 2020;15(8): e0236960.<pub-id pub-id-type="pmid">32813736</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhelankin</surname><given-names>AV</given-names></name><name><surname>Stonogina</surname><given-names>DA</given-names></name><name><surname>Vasiliev</surname><given-names>SV</given-names></name><name><surname>Babalyan</surname><given-names>KA</given-names></name><name><surname>Sharova</surname><given-names>EI</given-names></name><name><surname>Doludin</surname><given-names>YV</given-names></name><etal/></person-group><article-title>Circulating extracellular miRNA analysis in patients with stable CAD and acute coronary syndromes</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><issue>7</issue><fpage>962</fpage><pub-id pub-id-type="doi">10.3390/biom11070962</pub-id><?supplied-pmid 34209965?><pub-id pub-id-type="pmid">34209965</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Zhelankin AV, Stonogina DA, Vasiliev SV, Babalyan KA, Sharova EI, Doludin YV, et al. Circulating extracellular miRNA analysis in patients with stable CAD and acute coronary syndromes. Biomolecules. 2021;11(7):962.<pub-id pub-id-type="pmid">34209965</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Fichtlscherer</surname><given-names>S</given-names></name><name><surname>De Rosa</surname><given-names>S</given-names></name><name><surname>Fox</surname><given-names>H</given-names></name><name><surname>Schwietz</surname><given-names>T</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Liebetrau</surname><given-names>C</given-names></name><etal/></person-group><article-title>Circulating microRNAs in patients with coronary artery disease</article-title><source>Circ Res</source><year>2010</year><volume>107</volume><issue>5</issue><fpage>677</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.215566</pub-id><?supplied-pmid 20595655?><pub-id pub-id-type="pmid">20595655</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107(5):677&#x02013;84.<pub-id pub-id-type="pmid">20595655</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Dickinson</surname><given-names>BA</given-names></name><name><surname>Semus</surname><given-names>HM</given-names></name><name><surname>Montgomery</surname><given-names>RL</given-names></name><name><surname>Stack</surname><given-names>C</given-names></name><name><surname>Latimer</surname><given-names>PA</given-names></name><name><surname>Lewton</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure</article-title><source>Eur J Heart Fail</source><year>2013</year><volume>15</volume><issue>6</issue><fpage>650</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1093/eurjhf/hft018</pub-id><?supplied-pmid 23388090?><pub-id pub-id-type="pmid">23388090</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Dickinson BA, Semus HM, Montgomery RL, Stack C, Latimer PA, Lewton SM, et al. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail. 2013;15(6):650&#x02013;9.<pub-id pub-id-type="pmid">23388090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name></person-group><article-title>Circulating miR-106b-5p serves as a diagnostic biomarker for asymptomatic carotid artery stenosis and predicts the occurrence of cerebral ischemic events</article-title><source>Vasc Med</source><year>2020</year><volume>25</volume><issue>5</issue><fpage>436</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1177/1358863X20929424</pub-id><?supplied-pmid 32558619?><pub-id pub-id-type="pmid">32558619</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Zhang T, Chen Z, Yang X, Fu R, Wang J, Xu H. Circulating miR-106b-5p serves as a diagnostic biomarker for asymptomatic carotid artery stenosis and predicts the occurrence of cerebral ischemic events. Vasc Med. 2020;25(5):436&#x02013;42.<pub-id pub-id-type="pmid">32558619</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Elgebaly</surname><given-names>SA</given-names></name><name><surname>Christenson</surname><given-names>RH</given-names></name><name><surname>Kandil</surname><given-names>H</given-names></name><name><surname>El-Khazragy</surname><given-names>N</given-names></name><name><surname>Rashed</surname><given-names>L</given-names></name><name><surname>Yacoub</surname><given-names>B</given-names></name><etal/></person-group><article-title>Nourin-dependent miR-137 and miR-106b: novel early inflammatory diagnostic biomarkers for unstable angina patients</article-title><source>Biomolecules [Internet]</source><year>2021</year><volume>11</volume><issue>3</issue><fpage>368</fpage><pub-id pub-id-type="doi">10.3390/biom11030368</pub-id><?supplied-pmid 33670982?><pub-id pub-id-type="pmid">33670982</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Elgebaly SA, Christenson RH, Kandil H, El-Khazragy N, Rashed L, Yacoub B, et al. Nourin-dependent miR-137 and miR-106b: novel early inflammatory diagnostic biomarkers for unstable angina patients. Biomolecules [Internet]. 2021;11(3):368.<pub-id pub-id-type="pmid">33670982</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>M</given-names></name></person-group><article-title>MiR-19a overexpression contributes to heart failure through targeting ADRB1</article-title><source>Int J Clin Exp Med</source><year>2015</year><volume>8</volume><issue>1</issue><fpage>642</fpage><lpage>649</lpage><?supplied-pmid 25785039?><pub-id pub-id-type="pmid">25785039</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Miao Y, Chen H, Li M. MiR-19a overexpression contributes to heart failure through targeting ADRB1. Int J Clin Exp Med. 2015;8(1):642&#x02013;9.<pub-id pub-id-type="pmid">25785039</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>